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Abstract  
Introduction  
Recent advances in microarray technology have allowed more understanding of the complex 
molecular biology of breast cancer. The traditional prognostic information afforded by 
hormone receptor status and pathology variables is being supplemented and superseded by 
gene signatures predictive of risk of recurrence and response to treatments. Approximately 
75% of breast cancers are oestrogen receptor positive (ER+) and can be treated by drugs that 
block oestrogen production such as letrozole. However not all ER+ tumours respond and even 
those that initially respond can develop resistance.   
Treating patients with neoadjuvant letrozole affords a unique opportunity to sample the same 
tumour in vivo at different time points reducing any potential inter-patient and inter-tumour 
variability. The molecular effects of drugs can be assessed long before clinical outcome is 
apparent. Underlying genetic differences or characteristics of the patient, tumour or sample 
may affect the molecular response to treatment.  
This project set out to use sequential patient-matched samples to evaluate molecular changes 
in breast tumours in the presence or absence of endocrine treatment in different subtypes, 
defined by histology or mutation status and to assess molecular variation between primary 
tumour and nodal metastasis.  
 
Methods  
RNA was extracted and processed to generate whole transcriptome Illumina Beadarray gene 
expression data from four unique cohorts of patients. Clinical data on treatments, recurrence 
and survival was collected from medical records.  
The first cohort compared 25 breast cancer patients with matched samples at diagnosis and at 
surgery, 14-35 (median 23) days later, with no intervening treatment; with 36 patients treated 
with neoadjuvant letrozole.  
A PCR assay to detect 8 known PIK3CA mutations and assessment of PTEN status was 
performed at both the primary and secondary event in a second cohort of 120 patients with 
endocrine treated disease who relapsed with either recurrence, lymph node metastases, a new 
second primary or progression of disease on primary endocrine therapy.  
The third cohort compared the molecular response to neoadjuvant letrozole in 14 patients with 
invasive lobular cancer (ILC) and 14 patients with invasive ductal cancer (IDC). 
A fourth cohort of women with node positive disease at diagnosis were assessed for variations 
in gene expression profiles between primary tumour and synchronous metastatic axillary 
lymph nodes (68 samples from 31 patients).  
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Results  
The genomic profile of the no intervening treatment cohort did not differ significantly. Some 
changes in inflammatory genes were evident. This reassures us that changes seen during 
treatment are truly due to drug effect. This validates the use of a second biopsy to explore 
prediction of response.  
PIK3CA mutation status is maintained in the majority of patients with endocrine resistant 
disease and changed in only 15.7%. Where there was a change in PIK3CA this was 
significantly more likely to be a second primary breast cancer rather than a recurrence or 
progression of the primary cancer. PTEN status was also maintained in most patients. This 
does not support the theory that acquisition of a PIK3CA mutation is responsible for 
developing endocrine resistance. Novel PI3K inhibitor drugs may still be suitable in 
endocrine-resistant disease if activation of the pathway develops by other mechanisms.  
Consistent with previous studies, significant molecular differences were observed between 
ILC and IDC pre-treatment. Over half of these molecular differences were maintained after 3 
months of letrozole. However, changes over time in individual tumours in response to letrozole 
were highly consistent in both ILC and IDC.  
When comparing primary with synchronous metastatic nodes only 39% of tumours clustered 
together with their matched primary or node. The molecular subtype of the node was often a 
poorer prognosis than the primary. There were also differences in subtype between nodes in a 
small cohort of patients with 2 involved nodes.  
 
Conclusions  
We have demonstrated that neoadjuvant window studies are a valid model for assessment of 
drug effects and evaluated differences in histology and mutation status. 
Endocrine resistance in breast cancer is rarely related to acquisition of PIK3CA mutations.  
Synchronous lymph node metastases can differ greatly from their matched primary. These 
findings are highly relevant when considering prescribing (neo)/adjuvant therapy and have 
significantly improved our understanding of breast cancer as we strive towards personalised 
medicine. 
  
     
   5  
Lay  Summary  
Introduction  
Recent technological advances have allowed researchers to measure the level of large numbers 
of genes simultaneously. We can identify which genes are active in cancer and how the level 
of these genes changes with effects of treatment and time. In breast cancer, this has given rise 
to numerous ‘predictive gene signatures,’ where measuring the level of a small number of 
genes can give information about risk of disease progression and can identify patients suitable 
for certain specific treatments. This is now used to supplement the traditional staging 
information given by features of the cells of the tumour assessed by a pathologist using a 
microscope.  
75% of breast cancers possess the oestrogen receptor and these tumours can be treated with 
anti-oestrogen drugs, such as letrozole. However not all of these tumours respond and some 
who do respond initially then relapse later. Understanding the mechanism by which tumours 
achieve this is crucial in advancing treatment.  
This project explores the genetic profiles of serial samples taken from the same patient and 
cancer at different periods in time, treatment and different sites of disease, in order to assess 
changes in the molecular profiles of the tumour at these points.  
 
Methods  
Measurements of gene levels were made from samples of tumours collected from patients 
before and during treatment. Information on treatments, recurrence and survival was collected 
from patient medical records. 4 unique cohorts of patients were included.  
The first cohort compared 25 breast cancer patients with matched samples at diagnosis and at 
surgery, 14-35 (median 23) days later, with no treatment in the intervening period; with 36 
patients treated with pre-operative letrozole.  
The second cohort included 120 patients with endocrine-treated disease who relapsed with 
either recurrence, lymph node metastases, a new second primary, or progression of disease on 
primary endocrine therapy. A method to detect 8 known genetic mutations of a cancer pathway 
gene – PIK3CA, was performed on the tumour at both primary and secondary event. 
The third cohort compared the gene changes during treatment with letrozole in two groups of 
14 patients with the 2 most common subtypes of breast cancer, known as ‘lobular’ and ‘ductal.’ 
A fourth cohort of women with evidence of cancer spread from the breast to their lymph nodes 
at diagnosis were assessed for variations in gene expression profiles between the breast tumour 
and the lymph node tumour (68 samples from 31 patients).  
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Results  
The gene profiles of the tumours with no intervening treatment do not differ significantly. 
Some changes in inflammatory genes were evident. This reassures us that changes seen during 
treatment are truly due to drug effect. This validates the use of a second biopsy to explore 
prediction of response.  
PIK3CA mutation status is maintained in the majority of patients with endocrine resistant 
disease and changed in only 15.7%. Where there was a change in PIK3CA this was 
significantly more likely to be a second primary breast cancer rather than a recurrence or 
progression of the primary cancer. This does not support the theory that acquisition of a 
PIK3CA mutation is responsible for developing endocrine resistance. Novel drugs inhibiting 
this cancer pathway may still be suitable in endocrine resistant disease if activation of the 
pathway develops by other mechanisms.  
Consistent with previous studies, significant differences in levels of genes were observed 
between the lobular and ductal types of breast cancer pre-treatment. Over half of these 
molecular differences were maintained after 3 months of treatment with letrozole. However, 
changes over time in individual tumours were highly consistent in both subtypes of breast 
cancer.  
When comparing breast primary tumours with lymph node tumours only 39% of cases 
clustered together with their matched primary or node. The subtype of the node based upon 
levels of genes was often a poorer prognosis than the primary. There were also differences in 
subtype between nodes in a small cohort of patients with 2 involved nodes.  
 
Conclusions  
We have demonstrated that pre-operative window studies are a valid model for assessment of 
drug effects and evaluated differences in histology and mutation status. 
Endocrine resistance in breast cancer is rarely related to acquisition of PIK3CA mutations.  
Lymph node metastases can differ greatly from their matched primary. These findings are 
highly relevant when considering prescribing targeted treatments and have significantly 
improved our understanding of breast cancer as we strive towards personalised medicine. 
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Thesis  Organisation  and  Structure  
The results chapters (2-5) within this thesis are presented in the style of international peer-
reviewed journal articles. Chapters 3 and 4 have been published as presented in the thesis and 
Chapter 2 was presented at San Antonio Breast Cancer Symposium 13th December 2013 and 
published after expanding with additional samples and further analysis. Chapter 5 was 
presented as a poster at San Antonio Breast Cancer Symposium 7th December 2016. The 
Figure and Table numbers have been modified to make them more coherent in the context of 
the overall thesis. A single unified reference list has been created. It is hoped that the result is 
a clear and concise thesis summarising the valuable contributions of this doctoral project. Brief 
descriptions of the contributions of others to these chapters and the details of the publications 
are given below. 
 
Chapter 2 – 18 paired RNA samples (9 patients) were extracted by Dr Vicky Sabine from a 
previous study funded by GlaxoSmithKline. RNA from the other 32 samples was extracted by 
myself. All RNA was further processed for microarray by myself. The letrozole treated cohort 
(n=72 samples, 36 patients) used as comparison was constructed by Dr Arran Turnbull from 
work in his PhD.  
Pearce DA, Arthur LM, Turnbull AK, Renshaw L, Sabine VS, Thomas JS, Bartlett JM, Dixon 
JM, Sims AH. (2016) Tumour sampling method can significantly influence gene expression 
profiles derived from neoadjuvant window studies Sci Rep. 6:29434. PMID: 27384960 
 
Chapter 3 – DNA extraction and PIK3CA mutation PCR assay performed by Genentech, San 
Francisco. PTEN IHC performed by Histogenix, Belgium.  
Arthur LM, Turnbull AK, Renshaw L, Keys J, Thomas JS, Wilson TR, Lackner MR, Sims 
AH, Dixon JM. (2014) Changes in PIK3CA mutation status are not associated with recurrence, 
metastatic disease or progression in endocrine-treated breast cancer.  Breast Cancer Res Treat. 
147(1):211-9. PMID: 25104442 
 
Chapter 4 – Raw data composed by Dr Arran Turnbull previously. I acknowledge and am 
very thankful for the work in advanced bioinformatics analysis by Dr Andy Sims. 
Arthur LM, Turnbull AK, Webber VL, Larionov AA, Renshaw L, Kay C, Thomas JS, Dixon 
JM, Sims AH. (2014) Molecular changes in lobular breast cancers in response to endocrine 
therapy. Cancer Res. 74(19):5371-6. PMID: 25100562 
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Chapters 2 and 4 - The letrozole treated cohorts in these chapters were part of a larger cohort 
constructed and analysed previously by Dr Arran Turnbull, used to develop a 4-gene model 
predictive of response to neoadjuvant letrozole. I contributed to the following publication in 
assisting with development of the PCR and IHC techniques to implement the predictive model. 
Turnbull AK, Arthur LM, Renshaw L, Larionov AA, Kay C, Dunbier AK, Thomas JS, 
Dowsett M, Sims AH, Dixon JM. (2015) Accurate prediction and validation of response to 
endocrine therapy in breast cancer. J Clin Oncol. 33(20):2270-8. PMID: 26033813 
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AQUA   Automated  quantitative  analysis  
AR   Androgen  receptor  
ASCO   American  Society  for  Clinical  Oncology  
ASPM   Abnormal  spindle  microtubule  assembly  
ATF-­3   Activating  transcription  factor  3  
ATLAS   Adjuvant  Tamoxifen:  Longer  Against  Shorter  
BCI   Breast  cancer  index  
BELLE-­2   Buparlisib  helps  overcome  endocrine  resistance  in  metastatic  breast  cancer  
BIG   Breast  International  Group  
BL   Baseline  
BLAST   Basic  Local  Alignment  Search  Tool  
BOLERO-­2   Breast  Cancer  Trials  of  Oral  Everolimus-­2  
BRCA   Breast  and  ovarian  cancer  susceptibility  protein  
BRF2   B  related  factor  2  
BUB1   Budding  uninhibited  by  benzimidazoles  
CA12   Carbonic  anhydrase  12  
CAV1   Caveolin  1  
CCNB1   Cyclin  B1  
CCND1   Cyclin  D1  
CDC2   Cell  division  control  protein  2  homolog  
CDH1   E-­Cadherin  encoding  gene  
CDK   Cyclin  dependent  kinases  
cDNA   Complementary  DNA  
CI   Confidence  interval  
CK  5/6   Cytokeratin  5/6  
CKS2   CDC28  protein  kinase  regulatory  subunit  2  
CNAs   Copy  number  aberrations  
COL1A1   Collagen  type  1  alpha  1  chain  
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COLEC12   Collectin  subfamily  member  12  
CONFIRM   Comparison  of  Faslodex  in  Recurrent  or  Metastatic  Breast  Cancer  
CSC   Cancer  stem  cell  
CTC   Circulating  tumour  cells  
ctDNA   Circulating  cell-­free  tumour  DNA  
CXCL12   C-­X-­C  motif  chemokine  ligand  12  
CXCR4   Chemokine  receptor  
CYP19   Cytochrome  P450  enzyme  gene,  encodes  aromatase  
DAVID   Database  for  Annotation  Visualization  and  Integrated  Discovery  
DCIS   Ductal  carcinoma  in  situ  
DFS   Disease  free  survival  
DNA   Deoxyribonucleic  acid  
DNMTs   DNA  methytransferases  
DPT   Dermatopontin  
ECM   Extracellular  matrix  
EGFR   Human  epidermal  growth  factor  receptor  
EP  /  EPclin   Endopredict  /  EndopredictClin  
EPCAM   Epithelial  cell  adhesion  molecule  
ER  /  ER+   Oestrogen  receptor  /  Oestrogen  receptor  alpha  positive  
ERBB2   Erb-­B2  receptor  tyrosine  kinase  2  
ERE   Oestrogen  response  element  
ESM1   Endothelial  cell  specific  molecule  1  
ESR1   Gene  encoding  oestrogen  receptor  alpha  
ET   Endocrine  therapy  
et  al   Et  alia  
FALCON   Fulvestrant   500mg   versus   anastrozole   1mg   for   hormone   receptor-­positive  
advanced  breast  cancer  
FDR   False  discovery  rate  
FFPE   Formalin  fixed  paraffin  embedded  
FGFR   Fibroblast  growth  factor  receptor  
FIRST   Fulvestrant  First-­Line  Study  Comparing  Endocrine  Treatments  
FISH   Fluorescence  in  situ  hybridisation  
FLT1   Fms  related  tyrosine  kinase  1  
FOSB   FosB  proto-­oncogene  
FOXA1   Forkhead  box  A1  
G1-­Phase   Gap  1  phase  
GATA3   GATA  binding  protein  3  
GEO   Gene  expression  omnibus  
GGI   Genomic  Grade  Index  
GIDE   Global  Index  of  Dependence  on  oEstrogen  
GnRH   Gonadotrophin  releasing  hormone  agonists  
GRB7   Growth  factor  receptor  bound  proteins  
GSEA   Gene  set  enrichment  analysis  
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H:I  ratio   HOXB13:IL7BR  ratio  
H&E   Haematoxylin  and  Eosin  
HCL   Hierarchical  clustering  
HDACs   Histone  deacetylases  
HER2  /  3  /  4   Human  epidermal  growth  factor  receptor  2  /  3  /  4  
HGF   Hepatocyte  growth  factor  
HNF3   Hepatocyte  nuclear  factor  3  
HR   Hazard  ratio  
IC   Integrated  cluster  
ID   Identifier  
IDC   Invasive  ductal  carcinoma  
IER2   Immediate  early  response  2  
IGF  /  R  /  BP   Insulin-­like  growth  factor  /  receptor  /  binding  protein  
IHC   Immunohistochemistry  
IL6ST   Interleukin  6  signal  transducer  
ILC   Invasive  lobular  carcinoma  
IMPACT   Immediate  Preoperative  Anastrozole,  Tamoxifen,  or  Combined  with  Tamoxifen  
INPP4B   Inositol  polyphosphate-­4-­phosphatase  type  II  B  
ITGB2   Integrin  subunit  beta  2  
LCIS   Lobular  carcinoma  in  situ  
LETM2   Leucine  zipper  and  EF  hand  containing  protein  
LN   Lobular  neoplasia  
LREC   Local  research  ethics  committee  
MADP2   Mitotic  feedback  control  protein  2  homolog  
MAP  /  K   Mitogen  activated  protein  /  kinase  
MBD   Methyl-­CpG-­binding  domain  
MCM4  /  6   Minichromosome  maintenance  complex  component  4  /  6  
MDS   Multidimensional  scaling  plot  
MDT   Multi-­disciplinary  team  
METABRIC   Molecular  Taxonomy  of  Breast  Cancer  International  Consortium  
MGI   Molecular  grade  index  
MGPS   MultiGene  Proliferation  Score  
MINDACT   Microarray   In   node   negative   and   1-­3   positive   lymph   node   disease  may   avoid  
chemotherapy  
MKLP   Mitotic  kinesin-­like  protein  
MMP   Matrix  metallopepitadase/metalloproteinase  
MONALEESA-­2   Mammary  oncology  assessment  of  LEE011’s  (Ribociclib’s)  Efficacy  and  Safety  
MRI   Magnetic  resonance  imaging  
mRNA   Messenger  ribonucleic  acid  
MTAP   Methylthioadenosine  phosphorylase  
mTOR   mammalian  Target  of  Rapamycin  
MYBL2   MYB  proto-­oncogene  like  2  
MYC   V-­Myc  avian  myelocytomatosis  viral  oncogene  homolog  
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N     Node  
n   Sample  size  
N-­COR   Nuclear  receptor  corepressor  
NEDD9   Neural  precursor  cell  expressed  developmentally  down-­regulated  9  
NEOCENT   Neoadjuvant  Endocrine  vs  Chemotherapy  Trial  
neoMONARCH   A  Neoadjuvant  Study  of  Abemaciclib   (LY2835219)   in  Postmenopausal  Women  
with  Hormone  Receptor  Positive,  HER2  Negative  Breast  Cancer  
NPI   Nottingham  Prognostic  Index  
NR   Not  recorded  
NR3C2   Nuclear  receptor  subfamily  3  group  c  member  2  
OS   Ovarian  suppression  
P   Primary  tumour  
p  value   probability  
PALOMA  2   Palbociclib:  Ongoing  trials  in  management  of  breast  cancer  
PALOMA-­3   Fulvestrant   plus   palbociclib   versus   fulvestrant   plus   placebo   for   treatment   of  
hormone-­receptor-­positive,   HER2-­negative   metastatic   breast   cancer   that  
progressed  on  previous  endocrine  therapy  
PANTHER   Protein  analysis  through  evolutionary  relationships  
PCNA   Proliferating  cell  nuclear  antigen  
PCR   Polymerase  chain  reaction  
pCR   Pathological  complete  response  
PDE4B   Phosphodiesterase  4B  
PDK1   Pyruvate  dehydrogenase  kinase  1  
PELP1   Proline  glutamate  and  leucine  riche  protein  1  
PEPI   Preoperative  Endocrine  Prognostic  Index  
PFP   Percent  false  present  
PFS   Progression  free  survival  
PGAP3   Post  GP1  attachment  proteins  
PgR   Progesterone  receptor  encoding  gene  
PI3K   Phosphatidylinositol  3-­kinase  
PIK3CA/B   Phosphatidylinositol-­4,5-­biphosphate  3-­kinase  catalytic  subunit  a/b  
PIK3R1   Phosphoinositide-­3-­kinase  regulatory  subunit  1  
PLIN1   Perilipin  1  
POETIC   PeriOperative  Endocrine  Therapy:  Individualizing  Care  
PPAPDC1B   Phosphatidate  phosphatase  
PPP2R2A   Protein  phosphatase  2  regulatory  subunit  alpha  
PR   Progesterone  receptor  
PROACT   Preoperative  Anastrozole  Compared  with  Tamoxifen  
PTEN   Phosphatase  and  tensin  homolog  
qRT-­PCR   Quantitative  real  time  polymerase  chain  reaction  
RASTER   Microarray  prognostics  in  breast  cancer  
RB1   Retinoblastoma  tumour  suppressor  protein  
RECQL4   RecQ  Like  helicase  4  
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RFS   Recurrence  free  survival  
RNA   Ribonucleic  acid  
ROR   Risk  of  recurrence  
RP   Rank  products  
RR   Relative  risk  ratio  
RTKs   Receptor  tyrosine  kinases  
S-­phase   Synthesis  phase  
SD   Standard  deviation  
SERDs   Selective  oEstrogen  Receptor  Down-­regulators  
SERM   Selective  oEstrogen  Receptor  Modulator  
SET   Sensitivity  to  Endocrine  Therapy  
SNAI1   Zinc  finger  protein  
SoFEA   Study  of  Faslodex  with  or  without  concomitant  Armidex  vs  Exemestane  following  
progression  on  non-­steroidal  Aromatase  inhibitors  
SOFT   Suppression  of  Ovarian  Function  Trial  
SPDEF   SAM  Pointed  Domain  Containing  ETS  transcription  factor  
SPON1   Spondin  1  
SPP1   Secreted  phosphoprotein  1  or  osteopontin  
TAILORx   Trial  Assigning  Individualised  Options  for  Treatment  
TCGA   The  Cancer  Genome  Atlas  Network  
TDLU   Terminal  duct  lobular  unit  
TEXT   Tamoxifen  and  Exemestane  Trial  
TF   Transferrin  
TFF   Trefoil  factor  
TNBC   Triple  negative  breast  cancers  
TNFSF10   Tumour  necrosis  factor  superfamily  member  10  
TNM   Tumour  Node  Metastases  
TOP2A   Topoisomerase  2  alpha  
TP53   Tumour  protein  P53  
TTF   Transcription  termination  factor  
UK   United  Kingdom  
USA   United  States  of  America  
VEGF   Vascular  endothelial  growth  factor  
VWF   Von  Willebrand  Factor  
WT   Wild  type  
XBP1   X-­box  binding  protein  1  
ZEB1   Zinc  finger  Ebox  binding  
1   Background  
 
1.1   Breast  cancer  -­  incidence  and  survival    
Breast cancer is the most common female cancer in Scotland, with women currently facing a 
lifetime risk of 1 in 8.4 of developing the disease. In 2014, 4,610 new cases were diagnosed, 
representing 28.3% of all female cancers and 14.5% of male and female cancers [1]. Overall 
incidence is increasing, in part reflecting an extension of the Scottish Breast Screening 
Programme upper age limit to 70, as of April 2003, and also an increased uptake of breast 
screening services [2]. Despite increasing incidence, overall mortality is decreasing, 
representing the improved treatment options that are available and the detection of tumours at 
an earlier stage of disease. In 2014 breast cancer in Scotland contributed to 976 deaths, 




Figure  1-­1.  Annual  incidence  and  mortality  of  breast  cancer  in  Scotland  




1.2   Breast  anatomy  
The breast is composed of a series of ducts extending peripherally and branching multiply to 
secretory glands (acini). 15-20 segments or lobules containing acini drain to around 12 main 
ducts at the nipple. Ducts branch repeatedly until giving rise to the terminal duct lobular unit 
(TDLU), figure 1-2A. It is here carcinomas arise. The glandular component of normal breast 
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fluctuates with hormonal change throughout the menstrual cycle, pregnancy and the 
menopause. The remaining breast tissue is composed of fatty and fibrous stroma. After the 
menopause the relative proportion of glandular tissue is less and stroma more [3]. The ducts 





Figure  1-­2.  Breast  lobe  and  terminal  duct  lobular  unit  
A:  Schematic  representation  of  breast  ducts  and  lobules,  from  Hindle  WH  Breast  Care  
p34,  1999.    
B:   Haematoxylin   and   eosin   stained   FFPE   section   of   normal   breast   microscopy  
demonstrating   TDLU,   image   courtesy   of   Dr   Jeremy   Thomas,   Lead   Consultant  
Pathologist,  Edinburgh  Breast  Unit.    
 
1.3   Pathology  of  breast  cancer  
Breast cancer is a spectrum of diseases with varying clinicopathological features and 
outcomes. In assessing patients with breast cancer, we must identify features of prognosis, risk 
of recurrence, and markers predictive of response, in order to guide clinical decisions on 
treatment.  
 
1.3.1   Carcinoma  in  Situ  
Carcinoma in situ is a pre malignant change in the breast where neoplastic proliferation of 
cells occurs in the epithelium of the TDLU but does not breach the basement membrane [4]. 
It is further classified as ductal (DCIS) or lobular (LCIS). LCIS exists within a spectrum of 
lobular neoplasia (LN), which also encompasses atypical lobular hyperplasia (ALH). 
Distinguishing LCIS from ALH can be challenging. LN is associated with development of 
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DCIS or invasive breast cancer in the order of around 8-9% in LCIS and 2-3% in ALH [5]. 
Classic low and intermediate grade LCIS and pleomorphic LCIS should be treated by excision, 
however there may be a role for observation only in isolated ALH.  
 
DCIS often coexists with invasive disease and left untreated has potential to become invasive 
breast cancer [6]. Grading is based on cytonuclear staining and degree of necrosis into low, 
intermediate and high grade which corresponds to prognosis [7]. It is frequently associated 
with periductal and luminal microcalcifications seen on mammography, often in the screening 
programme, where it may occur in isolation.  
 
1.3.2   Invasive  breast  cancer  
70-75% of all breast cancers are invasive ductal carcinoma (IDC) of no special type. Invasive 
lobular carcinoma (ILC) accounts for a further 10-15% and the remainder are smaller 
histopathological subtypes including tubular, cribriform, mucinous, medullary-like, apocrine, 
metaplastic or mixed. Ductal and lobular breast cancers behave with distinct 
clinicopathological features. Histologically ILC is recognised by small round monomorphic 
cells in single file with pagetoid spread. There is often no significant surrounding invasion or 
connective tissue response [8]. This diffuse growth means there may be no distinct mass, 
making diagnosis clinically [9] and mammographically difficult [10]. ILC is more likely to be 
multifocal, multicentric [11] and bilateral [12].  LN and ILC are characterised by the loss of 
the intercellular adhesion molecule E-Cadherin expression [13], figure 1-3. 
 
 
Figure  1-­3.  Invasive  lobular  carcinoma  
A:  H&E  of  classical  ILC  with  distinguishing  features  highlighted.    
B:  Lack  of  immunohistochemical  staining  of  E-­Cadherin.  Images  -­    Dr  Jeremy  Thomas  
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1.3.3   Grading  breast  cancer  
Elston and Ellis proposed the current internationally accepted grading system where 
reproducible quantitative evaluation of three morphological features; namely acinar formation, 
nuclear atypia or pleomorphism, and mitotic count are assessed and used to calculate an overall 
grade of 1, 2 or 3 for each tumour, providing important prognostic information [14].  
 
1.3.4   Lymphovascular  invasion  
Lymphatic or blood vessel invasion, or both, is an indicator of poorer recurrence free and 
overall survival, independent of lymph node involvement or other tumour features [15]. 
 
1.3.5   Nodal  status    
Lymph node involvement is one of the most important prognostic factors in breast cancer, 
with prognosis deteriorating with increasing number of positive nodes [16]. Sentinel lymph 
node biopsy is the accepted method of staging the clinically and radiologically node negative 
axilla. Axillary lymph node dissection, with its associated morbidities, can be safely avoided 
in a negative sentinel node, and in patients with early breast cancer and a positive sentinel 
node [17]. Macrometastases are greater than 2mm diameter, micrometastases are 0.2-2mm 
diameter, and clusters of tumour cells measuring less than 0.2mm are termed isolated tumour 
cells. Micrometastases are associated with poorer prognosis [18], but the impact of isolated 
tumour cells detected in sentinel node biopsy is comparable to node negative disease [19] and 
therefore current Tumour Node Metastases (TNM) staging classify this as such. Extra nodal 
extension and invasion of adjacent lymphatics are also associated with poorer outcome [20].  
 
1.3.6   Predictive  Immunohistochemistry  
75% of invasive breast cancers express oestrogen receptor alpha (ER+), a favourable 
prognostic factor and a strong predictor of response to endocrine therapies. Levels of ER and 
the progesterone receptor (PR) are assessed by the Allred Score, based on proportion and 
intensity of immunohistochemistry (IHC) staining in the nucleus, as 0 to 8, with scores of 2 or 
above being considered positive. Expression of ER and PR not only predict response to 
endocrine therapies but also have a prognostic significance. Moderate to poor ER expressing 
tumours (Allred <6) have a poorer prognosis than those which are ER-rich (Allred 7-8) [21]. 
Similarly, higher expression of PR is associated with more favourable outcome also [22]. In 
ER+ / PR- disease around 40-60% of patients derive benefit from endocrine therapy, however 
in ER+ / PR+ disease around 75% will benefit [23]. In ER- / PR+ disease around 40% will 
benefit [24]. Human epidermal growth factor 2 (HER2), an oncogene protein, is positive in 
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15-20% of invasive cancers and is associated with poorer outcome [25] although its presence 
is predictive of response to numerous immunotherapies including trastuzumab (a monoclonal 
antibody against HER2), lapatinib (tyrosine kinase inhibitor), pertuzumab (HER2 / HER3 
dimerisation inhibitor) and trastuzumab emtansine (T-DM1), an antibody-drug conjugate 
which binds to HER2 and releases cytotoxic emtansine into the cell [26]. HER2, a 
transmembrane tyrosine kinase receptor, is assessed by IHC as 0, 1+ (negative), 2+ or 3+ 
(positive). Samples of 2+ are further assessed by fluorescence in situ hybridisation (FISH) to 
determine gene copy numbers to classify as positive or negative. 
 
1.3.6.1   Ki67    
Ki67 is a nuclear antigen and marker of proliferation which can be assessed by IHC. It is a 
valid prognostic indicator [27] and a marker of response to neo-adjuvant (pre-operative) 
chemotherapy [28] and endocrine therapy [29], when measured after an initial period of 
treatment, which can be as short as two weeks [30]. Ki67 has also been demonstrated as a 
marker of poorer recurrence free survival in subgroup analyses of node-negative, node-
positive and untreated patients in a meta-analysis of 12,155 patients from 46 studies [31]. 
There has been difficulty establishing a reproducible and reliable method of measuring Ki67. 
There is risk of pathologist and institution dependent bias, and there is wide discrepancy about 
absolute values to be considered as ‘high’ or ‘positive’ as opposed to ‘low’ or ‘negative’. The 
International Ki67 in Breast Cancer Working Group have developed recommendations for the 
gold standard method of assessing Ki67 in research trials [32].  This is favourable over semi 
quantitative imaging techniques, such as automated quantitative analysis (AQUA) [33], 
Automated Cellular Imaging System (ACIS) [34], or Scanscope [35]; which are validated 
methods of measurement of Ki67 expression, but are not routinely available in all centres.  
 
1.4   Microarray  technology  and  molecular  pathology  of  breast  cancer  
Advances in high-throughput genomic technologies have augmented and reformed our 
understanding of breast cancer [36, 37]. Breast cancer is a highly complex and heterogeneous 
disease, highlighted by the numerous differences in clinicopathological features and varying 
responses to therapy seen in different tumours and patients. The high-throughput technologies 
provide simultaneous measurement of thousands of DNA sequences, RNA transcripts, 
peptides and metabolites giving a holistic overall portrait of complex tumour biology. Gene 
expression profiling in particular has been applied to many areas of research, with the potential 
to identify new targets for treatment, mechanisms of resistance and to improve on current tools 
for the analysis of prognosis [38, 39]. Broadly, a ‘top-down’ or ‘bottom-up’ approach to gene 
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expression analyses may be employed. Initial classification used a top-down approach, 
whereby samples of tumours from many patients were profiled, and candidate gene signatures 
which clustered together were identified, which could discriminate between patient groups 
based on similarities across thousands of genes or active pathways. In bottom-up analyses, a 
single or multigene predictor derived from in vivo or in vitro experiments corresponding to a 
phenotype, or resistance to a drug, is then applied to breast cancer samples [40].  
 
1.4.1   Gene  expression  profiling  intrinsic  subtypes  
Perou et al hypothesised that the phenotypic variation in breast cancers may be mirrored with 
diversity in gene expression, and using unsupervised hierarchical clustering on cDNA 
microarrays from 42 patients, proposed a molecular taxonomy of four molecular subtypes of 
breast cancer, based on differential expression of 496 intrinsic genes [41]. The four subtypes; 
basal-like, normal-like, ERBB2-enriched and luminal, were further classified into five 
subtypes with the distinction of a luminal A and poorer prognostic luminal B subtype by Sorlie 
et al [42] in 2001. They recognised each subtype was prognostic and later demonstrated 
subtype classification was reproducible across multiple microarray platforms [43]. Each 
subtype has distinct clinical outcomes and pathological features, figure 1-4. 
 
1.4.1.1   Luminal  A  
Luminal A is the most commonly occurring subtype, accounting for 54% of all breast cancers 
[44]. It has high expression of ESR1, the gene encoding ERα, and a molecular profile 
resembling the luminal epithelial component of breast tissue; including expression of luminal 
cytokeratins 8 and 18, and genes associated with ER activation, including GATA binding 
protein 3 (GATA3), X-box binding protein 1 (XBP1), trefoil factor 3 (TFF3), hepatocyte 
nuclear factor 3 (HNF3), oestrogen-regulated LIV-1, and cyclin D1 (CCND1). Tumours are of 
lower grade and have a favourable prognosis [45] with a 10 year recurrence free survival of 
over 80% [46].  
 
1.4.1.2   Luminal  B  
Luminal B tumours have lower expression of ER related genes and higher expression of 
proliferation associated and cell cycle genes including RecQ Like helicase 4 (RECQL4), cyclin 
B1 (CCNB1), MYB proto-oncogene like 2 (MYBL2), ASH2 like (ASH2L), B related factor 2 
(BRF2), phospholipase DDHD2, fibroblast growth factor receptor 1 (FGFR1), leucine zipper 
and EF hand containing protein (LETM2), LSM1, and phosphatidate phosphatase 
(PPAPDC1B) [47]. Tumours are ER+, high grade with high Ki67. Gene set enrichment 
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analysis (GSEA) has identified activation of growth factor signalling, including ERBB2, 
however only 10-20% of tumours are positive for HER2 by IHC [48]. They respond less well 
to endocrine therapy than luminal A tumours, and less well to chemotherapy than basal and 
HER2 subtypes [49]. Overall they have a poorer prognosis than luminal A with increased risk 
of early relapse [50] and poorer disease free survival. Both Luminal A and B have a 
predisposition to metastasise to bone and pleura [51]. 
 
1.4.1.3   HER2-­enriched  
HER2 tumours are characterized by high expression of several genes in the ERBB2 amplicon 
at 17q22.24 including ERBB2, Growth factor receptor bound proteins (GRB7), and post GP1 
attachment to proteins (PGAP3) [41, 42]. They are more likely to be grade 3 and 40-80% 
harbour a mutation in the tumour suppressor gene TP53 [52]. HER2 subtype has a poorer 
prognosis than luminal disease, but is sensitive to anthracycline and taxane based neoadjuvant 
chemotherapy with higher levels of pathological complete response (pCR) than in luminal 
tumours [53]. It is important to realise that not all tumours deemed HER2+ by IHC and FISH 
are HER2 enriched at transcription level, and a proportion of these are luminal subtype [54].  
 
1.4.1.4   Basal-­like  
Basal-like tumours are ER- PR- HER2- (triple negative breast cancers, TNBC), and are high 
grade, highly proliferative with a poor prognosis [42]. They account for 10-25% of all breast 
cancers. Expression profiles resemble basal epithelial cells and normal breast myoepithelial 
cells with high expression of cytokeratins 5, 6, 14 and 17 [41], metallothionein, integrin B4, 
P-cadherin, laminin, and fatty acid binding protein 7 [46, 55]. Incidence is higher in African 
American women, especially those premenopausal [56]. Typically tumours present as a large 
rapidly growing mass and radiologically can be ill defined, lobulated, mixed cystic and solid 
[57]. The majority of tumours in BRCA1 mutation carriers are of basal phenotype [58] and up 
to 80% of basal tumours have a TP53 mutation [59]. EGFR is over expressed in 40% [60] 
which may have a role in resistance to chemotherapy. 
 
1.4.1.5   Normal-­like  
The normal-like subtype expresses genes seen in adipose tissue, fibroadenomata and normal 
breast tissue including fatty acid binding protein and PPAR gamma [41]. They can be ER+ or 
ER-, and may express some basal epithelial genes therefore are difficult to distinguish from 
basal-like tumours by IHC only [61], although some researchers have adopted ER- PR- HER2- 
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CK5/6- EGFR- as being diagnostic of normal-like. It does however have a much more 




Figure  1-­4.  Molecular  subtypes  of  breast  cancer  
Spectrum  of  breast  cancer  and  associated  clinical  features.  It  should  be  noted  that  
classifying   tumours   based   on   their   IHC   hormone   receptor   status   does   not   always  
correspond  to  the  appropriate  molecular  subtype,  as  defined  by  mRNA  microarray,  
and  may  be  an  oversimplification;;  eg  a  proportion  of  tumours  HER2+  by  IHC  will  be  
luminal  subtype.  
AR  –  androgen  receptor,  CK  –  cytokeratin  
 
The Sorlie intrinsic subtypes have been widely adopted as a gold standard taxonomy in the 
breast cancer field, although alternative subtypes have also been proposed.  
 
Sotiriou et al identified 6 subtypes based on expression of 706 cDNA probes in 99 breast 
cancer specimens, including a third luminal subtype, 1 HER2-enriched, and 2 basal-like 
groups.  
Luminal 1 tumours had higher expression of c-kit, hepatocyte growth factor (HGF), insulin-
like growth factor binding-protein 3 (IGFBP-3), activating transcription factor 3 (ATF-3) and 
components of activating protein (AP-1) transcription factor, and lower expression of cell 
growth related genes, including topoisomerase 2α (TOP2A), mitotic kinesin-like protein 
(MKLP)-1, proliferating cell nuclear antigen (PCNA), cell division control protein 2 homolog 
(CDC2), BUB1 and MAD2L1; and were associated with 80% 10-year recurrence free survival 
(RFS).  
   29  
Luminal 2 subtype had higher expression of protein tyrosine phosphatase type IVA (PTP4A1), 
tumour necrosis factor receptor associated factor 3 (TRAF3), RAD21 and BRCA1-associated 
protein, and lower expression of fibroblast growth factor receptor (FGFR1), chemokine 
receptor (CXCR4), ATF-3 and vascular cell adhesion molecule 1 (VCAM-1); with a 10-year 
RFS of 40%.  
Luminal 3 subtype had intermediate 10-year RFS of 60%.  
Basal 1 subgroup had higher expression of matrix metalloproteinase-7 (MMP7) and cell 
growth-related and proliferation genes, including TOP2A, mitotic feedback control protein 2 
homolog (MADP2), CDC2 and PCNA.  
Basal 2 tumours had higher expression of transcription factor AP-1 components, including c-
Fos, c-Jun and Fos-B, and overexpression of transforming growth factor beta receptor 2, ATF-
3, caveolin 1 and 2, and HGF [46]. 
 
A further subtype of TNBC; the claudin-low group, characterised by low expression of claudin 
genes, notably 3, 4 and 7, and also E-cadherin [63], all of which are involved in cell-cell 
junctions, has been identified. Claudin-low tumours are similar but distinct from basal-like 
tumours. They have immune infiltrates, features of stem cells and epithelial mesenchymal 
transition, including zinc finger Ebox binding (ZEB1) and zinc finger protein (SNAI1) [63].  
 
Lehmann et al proposed 6 subtypes of TNBC; 2 basal-like, 1 immunomodulatory, 1 
mesenchymal, 1 mesenchymal stem-like and 1 luminal androgen receptor.  
Basal-like 1 subtype are enriched in cell cycle and cell division components and pathways 
with high proliferation.  
Basal-like 2 subtype are enriched for pathways in growth factor signalling, glycolysis and 
gluconeogenesis, and growth factor receptors.  
Immunomodulatory subtype is enriched in immune processes, including immune cell and 
cytokine signalling, antigen processing and presentation and complement cascade.  
Mesenchymal subtype has high expression of cell motility components and pathways, ECM 
receptor interaction and cell-differentiation pathways.  
Mesenchymal stem-like subtype is similar to mesenchymal, but also has genes relating to 
growth factor signalling pathway components and processes. It has low expression of claudins 
3, 4 and 7 (as in claudin-low subtype).  
The luminal androgen receptor subtype is ER- but has luminal gene expression patterns [64].  
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The molecular apocrine breast cancer subgroup is ER- and also characterised by androgen 
receptor (AR) expression and activation of AR signalling, including protein coding genes 
FOXA1, AGR2, and activated leukocyte cell adhesion molecule (ALCAM), transcription factor 
SPDEF, and TTF3 [65].  
 
1.4.2   Genomic  expression  profiling  subtypes  
Curtis et al described 10 integrative cluster (IntClust, IC) breast cancer subtypes in the 
Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) study; based 
on integrated genomic copy number and transcriptomic profiling in 2,000 patients. Clusters 
correlated with distinct clinical outcomes. Inherited genetic variants and acquired somatic 
copy number aberrations (CNAs) were associated with expression in >39% of genes; with 
most influence derived through CNAs acting in cis (influencing its own expression) or trans 
(affecting other gene expression also). They highlighted several genes as putative breast cancer 
tumour suppressor genes, including PPP2R2A, MTAP and MAP2K4. They proposed further 
sub-classification within the luminal subtypes.  
ICs-3,7 and 8 are predominantly luminal A, with IC-3 lacking copy number and genomic 
variants, IC-7 having 16p gain / 16q loss and 8q amplification, and IC-8 having 1q gain / 16q 
loss.  
IC-2 is a high risk luminal subtype, which harbours 11q13 / 14 aberrations, affecting CCND1 
and several oncogenes.  
ICs-1, 6 and 9 were predominantly luminal B subtype; associated respectively with 17q23 / 
20q cis aberrations; 8p12 cis aberrations and 8q cis aberrations / 20q amplifications.  
IC-5 incorporates an expanded ERBB-2 amplified group incorporating both ER+ and ER- 
tumours.  
IC-10 are basal subtype and the most unstable genomically. 
IC-4 included various transcriptional intrinsic subtypes but shared similar genomic features to 
IC-3 (lacking copy number and cis-acting alterations) [66]. 
 
The Cancer Genome Atlas Network (TCGA) integrated data from multiple platforms; genomic 
copy number arrays, DNA methylation, exome sequencing, mRNA, micro RNA, and reverse 
phase protein arrays to classify breast cancer into 4 subtypes; luminal A, luminal B, HER2-
enriched and basal-like. Subtypes were associated with particular gene mutations; with 
luminal A harbouring 45% PIK3CA mutations, followed by other most frequent mutations in 
GATA3, MAP3K1, TP53, CDH1, PIK3R1 and MAP2K4. Luminal B tumours had mutations in 
PIK3CA in 29% and TP53 in 29%. Basal tumours had TP53 mutations in 80%, but PIK3CA 
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mutations in only 9%. The HER2-enriched subtype was associated with ERBB-2 amplification 
in 80%, mutations in TP53 in 72% and PIK3CA in 39%, with lower levels of mutations of the 
luminal associated gene mutants, eg PIK3R1 mutations in only 4% [67].  
 
Molecular subtype classification in breast cancer is complex and far from standardised. 
Furthermore, whole genome arrays are costly and often require fresh frozen tissue samples; 
two factors which vastly limit their reproducibility in routine clinical care. To guide treatment, 
we must identify features of poor prognosis and those predictive of response to targeted 
therapies. Multiple classifiers have been proposed (see section 1.9), though not all are 
routinely used in UK clinical practice, and indeed not all are helpful in treatment decisions.  
 
Broadly, three subtypes are used to guide treatment;  
ER+ and / or PR+,  treated with ER+ targeted endocrine therapy,  
HER2+,  treated with targeted anti-HER2 agents, and  
TNBC,  treated with chemotherapy.  
 
1.5   Treatment  of  early  breast  cancer  
Following diagnosis and staging of breast cancer, a treatment plan will be proposed. In early 
disease, this is likely to involve surgery, either as first treatment or increasingly, following a 
period of pre-operative or neoadjuvant therapy. Adjuvant (post-operative) treatments 
including chemotherapy, radiotherapy and anti-HER2 therapy, are offered to appropriate 
patients thereafter, figure 1-5. Neoadjuvant treatment can be used to downstage large or locally 
advanced breast tumours, increasing rates of breast conserving surgery thereby avoiding 
mastectomy [68]. Neoadjuvant chemotherapy has been established in this role since the 1970s 
and more recently targeted endocrine and anti-HER2 agents have also been used in appropriate 
patients [69, 70]. A further advantage is a unique in vivo observation of tumour response to 
treatment [71]. Taking sequential biopsies from the same tumour in this ‘window of 
opportunity’ can potentially identify molecular subtypes or markers associated with response 
and resistance. This may identify patients unlikely to respond to a certain drug, who require 
alternative or combination therapies, and ultimately spare them from unnecessary and 
ineffective treatment. Longer term prognostic information can also be derived in this very 
early period. Response in the neoadjuvant setting, particularly pathological complete response, 
is associated with a favourable prognosis with improved disease free and overall survival in 
the longer term; especially in HER2-positive and triple negative breast cancer subtypes [72].  
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Figure  1-­5.  Treatment  of  early  breast  cancer  
Treatment  is  decided  on  an  individual  basis  reflecting  patient  host,  tumour  and  stage  
of  disease  factors.  Further  surgery  may  be  considered  in  women  undergoing  breast  
conservation  surgery  who  have  positive  margins  at  the  initial  resection.    
MDT  –  multi-­disciplinary  team.  
 
The remainder of this discussion will focus on endocrine treatments and ER+ breast cancer. 
Most ER+ disease will respond to endocrine therapies. Our challenge as clinicians is to identify 
clinical and biological features of poor prognosis or prediction of resistance in order that we 
target these patients with additional treatment. Equally we must also identify patients with 
such good prognostic features they can be spared from toxic adjuvant chemotherapy which 
may offer little advantage.  
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1.6   Oestrogen  and  oestrogen  receptor  (ER)  in  breast  cancer    
The role of oestrogen in the pathogenesis of breast cancer was first recognised by George 
Beatson in 1896  [73]. His experimental oophorectomy was the first form of endocrine therapy. 
It was later recognised that oestrogen modulated its effects on target tissues through specific 
proteins, namely oestrogen receptors (ER) [74, 75]. There are two isoforms of ER, ERα and 
ERβ, with ERα being predominant in ER+ breast cancer pathogenesis and treatments [76].  
 
The endogenous oestrogen, 17β-oestradiol (E2), enters cells and binds to the ligand binding 
domain (LBD) of ERα. There are two transcriptional activation domains of ERα, activating 
function (AF)1 in the amino terminal region, which is regulated by phosphorylation, and AF2 
in the carboxy-terminal region, which is regulated by ligand binding [77]. AF1 and AF2 
activate transcription independently and / or synergistically. E2 binds to the LBD of ERα (E2-
ER) in a strong but reversible way and enters the nucleus. The LBD is encoded by around 300 
amino acids and forms a wedge-shaped structure incorporating the ligand-binding pocket. 
When E2 binds at the LBD, ER activates in response undergoing conformational change, with 
dissociation of heat shock proteins and formation of a ligand-occupied ER dimer [78]. The 
conformational change in ER uncovers a surface that can recruit co-activators. It also results 
in dissociation of co-repressors [79]. The E2-ER binds as a dimer to small palindromic DNA 
sequences, known as oestrogen response elements (EREs) in the promotor regions of specific 
oestrogen regulated target genes (see figure 1-6). Co-activators bind histone acetyltransferases 
(HATs), leading to acetylation of histones and decondensation of chromatin, facilitating 
transcriptional activation. In its un-liganded state, ER is bound to corepressor complexes, 
which recruit histone deacetylases (HDACs)  [80]. Their function is to maintain histones is a 
deacetylated state which will favour chromatin condensation. 
 
ER can also interact with EREs through numerous transcription factors which help tether the 
receptor to DNA. The E2-ER is not directly bound to DNA, but interacts with other DNA 
bound proteins forming multiprotein complexes which augment binding of other transcription 
factors and prevent chromatin condensation. AP1 factors, such as JUN and FOS proteins, have 
been implicated in this role [81].  
 
ER activation is also possible in the absence of a ligand, mediated by phosphorylation of ER 
due to stimulation by alternate growth factors. Phosphorylation at several sites can increase 
ER activity, including at serine 118 within AF1. Serine 118 is phosphorylated by the mitogen 
activated kinases (MAPK), ERK1 and ERK2, and also by CDK7 [82]. AKT, a downstream 
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target of PI3K, phosphorylates ER at serine 167 in AF1 [83], also resulting in ligand 
independent activation. PI3K can be activated by cross talk from numerous growth factor 
pathways, including EGFR, HER2 and insulin-like growth factor receptor (IGF1R), 
potentially causing E2 independent activation of ER.  
 
Cyclin D1 is a direct transcription target of ER and other EGFR signalling pathways. Cyclin 
D1 activates cyclin dependent kinases (CDK) 4 and 6, and also activation of cyclin E and 
CDK2, both leading to downstream hyper-phosphorylation of retinoblastoma tumour 
suppressor protein (RB1) [84], thereby dissociating from and losing its inhibition of 
transcription factors, notably E2F family, activating genes required for progression from G1 
to S phase of the cell cycle [85]. 
 
1.7   Endocrine  therapy  in  ER+  breast  cancer  
Endocrine therapy in breast cancer targets either the oestrogen receptor, competitively binding 
or modulating ER to exert an antagonistic effect; or inhibits oestrogen biosynthesis to reduce 
circulating levels of E2 [86]. In premenopausal women, oestrogen is produced by the ovaries, 
whereas in postmenopausal women oestrogen is produced by enzymatic conversion of 
androgens (androstenedione and testosterone) to oestrogens (such as oestradiol and oestrone) 
by aromatase [87], figure 1-6. Aromatase is present most abundantly in adipose tissue, but also 
other sites including muscle [88], bone and brain. Aromatase is also present in normal breast 
and breast cancer tissue [89]. An alternative approach to endocrine therapy is required in pre 
and postmenopausal women.  
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Figure  1-­6.  Oestrogen  and  ER  in  breast  cancer,  mechanism  of  action  of  endocrine  
therapies  
Oestradiol  binds   to  ER,   receptor  dimerises,  undergoes  conformational  change  and  
binds   to   oestrogen   response   elements   (EREs)   upstream   of   oestrogen   responsive  
genes  necessary  for  proliferation.    
Aromatase   inhibitors  block   the   conversion  of   androgens   to  oestrogens.  Tamoxifen  
competitively  binds  with  ER.  
 
1.7.1   Anti-­oestrogens  –  SERMs    
Tamoxifen is a Selective oEstrogen Receptor Modulator (SERM) which mimics oestrogen 
binding to the ligand binding domain of ERα and is the mainstay of endocrine therapy in ER+ 
breast cancer in pre and peri-menopausal women [86]. Binding of tamoxifen to the ER LBD 
activates a similar cascade as seen with E2, however the resulting conformational change in 
the receptor is different. Activation of AF1 does occur but not activation of AF2, resulting in 
partial agonist and partial antagonist activity. Tamoxifen bound ER interacts with co-
repressors promoting their recruitment to AF2, and preventing recruitment of co-activators 
[90].   
 
Tamoxifen became first established as a tumouristatic agent in advanced breast cancer [91] in 
the 1970s, where it was noted to prevent disease progression for 1-2 years. In the adjuvant 
setting, 5 years of tamoxifen reduces the risk of breast cancer death by one third, and reduces 
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breast cancer recurrence by one half at 15 years [92, 93]. 5 years of therapy is superior to 1-2 
years [23]. Treatment is most effective in patients with high expression of ER [94]. The 
Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, demonstrated reduction in 
recurrence and improved survival at 15 years when tamoxifen was continued to 10 years 
compared with 5 [95], particularly during years 10-14. Toxicities, most commonly 
menopausal-like symptoms [96], can be problematic which can reduce compliance however. 
Tamoxifen is also associated with a relative risk ratio (RR) of twofold for development of 
venous thromboembolism (higher RR of 3.5 in first 2 years of treatment) [97], and also 
increased risk of endometrial hyperplasia and endometrial carcinoma of about 2.5 times [87], 
due to the presence of both agonist and antagonist properties specific to different tissues [98].  
 
Raloxifene, toremifene and arzoxifene are alternative SERMs. Raloxifene was initially 
licensed for osteoporosis prevention and treatment in postmenopausal women, but was also 
found to reduce the risk of developing breast cancer in the Multiple Outcomes Raloxifene 
Evaluation (MORE) study by 76% (13 of 5,129 patients with raloxifene, 27 of 2,576 with 
placebo; RR 0.24; 95% CI 0.13-0.44, p<0.001) [99]. Raloxifene, similar to tamoxifen, causes 
a twofold relative risk of thromboembolism [100], however no increased risk of endometrial 
cancer, because unlike tamoxifen, raloxifene lacks the agonist activity of uterine ER [101].  
 
There is limited evidence on the role of neoadjuvant endocrine therapy in premenopausal 
women. A study assessing 7 days of pre-operative tamoxifen in 44 patients (58% post-
menopausal, 32% pre or peri-menopausal) found a mean decrease in Ki67 of 40% (95% CI 
29-63%) [102]. The STAGE trial compared neoadjuvant anastrozole with tamoxifen in 
premenopausal women receiving goserelin (Gonadotrophin Releasing Hormone Agonist, 
GnRH) and found more patients had complete or partial response with anastrozole than 
tamoxifen (70.4% vs 50.5%; difference 19.9%, 95% CI 6.5-33.3, p=0.004) [103]. Many 
premenopausal patients will have features of adverse prognosis and be considered for 
neoadjuvant chemotherapy rather than endocrine therapy (see section 1.9).  
 
1.7.2   Anti-­oestrogens  -­  SERDs  
Unlike SERMs the role of SERDs has been established in postmenopausal rather than 
premenopausal women. Fulvestrant, (Faslodex), is a Selective oEstrogen Receptor 
Downregulator (SERD) which binds to ER and dissociates receptor proteins, in doing so 
accelerating receptor degradation so the rate of dimerization and nuclear localisation of the 
fulvestrant-ER complex is reduced. Binding to ERE is reduced, thereby transcription of ER 
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regulated genes are reduced [104]. It has poor oral bioavailability and is therefore administered 
by monthly intramuscular injection, following initial loading doses. In advanced disease, in 
patients previously treated with tamoxifen, fulvestrant is at least as effective as the aromatase 
inhibitor, anastrozole (see section 1.6.3) in delaying time to disease progression and treatment 
failure [105], at a monthly dose of 250mg. Evidence of a dose related response was apparent 
with a higher dose of 500mg achieving near 100% ER down-regulation compared to 70% 
down-regulation with a 250mg dose [106]. Indeed, increasing the dose to 500mg compared to 
250mg improved survival by a median of 4.1 months in the Comparison of Faslodex in 
Recurrent or Metastatic Breast Cancer (CONFIRM) trial of 736 women, who tolerated the 
higher dose well with no increased reported adverse events [107]. The Fulvestrant First-Line 
Study Comparing Endocrine Treatments (FIRST) trial found higher dose 500mg fulvestrant 
was non-inferior to anastrozole in time to disease progression in advanced and metastatic 
disease, and found higher dose fulvestrant was well tolerated, with 11% adverse events but 
only 3% discontinuing treatment [108]. At this planned initial end point the median time to 
progression had not been reached for fulvestrant and a subsequent follow up analysis 
confirmed significantly improved time to progression with fulvestrant over anastrozole (23.4 
vs 13.1 months, p=0.01) [109]. Recently, the fulvestrant 500mg versus anastrozole 1mg for 
hormone receptor-positive advanced breast cancer (FALCON) trial, confirmed fulvestrant to 
have superior efficacy in advanced and metastatic endocrine naive patients compared to 
anastrozole (median progression free survival 16.6 vs 13.8 months, p=0.048) [110]. This 
double-blind randomised multicentre trial of over 500 patients demonstrated slightly higher 
adverse events in the fulvestrant group (arthralgia 17% vs 10%) however similar 
discontinuation rates (7% vs 5%). Interestingly there was no improvement in overall survival. 
Most patients with metastatic ER+ disease will however have had one or more prior endocrine 
therapy, so further evaluation of fulvestrant in these patients will be necessary.  
 
1.7.3   Ovarian  suppression  
Ovarian suppression (OS) in premenopausal women can be achieved medically by 
gonadotrophin releasing hormone agonists (GnRH); surgically by oophorectomy, or by 
ablation with pelvic irradiation. Patients who experience chemotherapy-induced amenorrhoea 
in the treatment of ER+ breast cancer have improved survival [111]. The Suppression of 
Ovarian Function Trial (SOFT) did not however show improved disease free survival with the 
addition of OS to tamoxifen compared to tamoxifen alone across all unselected premenopausal 
ER+ patients [112]. In a cohort treated with exemestane plus OS however there was 7.7% 
improvement in recurrence free survival at 5 years compared to tamoxifen alone. Similarly, 
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the Tamoxifen and Exemestane Trial (TEXT) found exemestane plus OS superior to 
tamoxifen plus OS by 4 percentage points in disease free survival at 5 years [113]. A striking 
subgroup analysis in SOFT revealed young women under age 35 at diagnosis had the most 
benefit from OS with a 5 year breast cancer free incidence of 67.7% in tamoxifen alone, 78.9% 
for tamoxifen plus OS and 83.4% for exemestane plus OS; strongly supporting the roll of OS 
in this high risk population [111]. The American Society for Clinical Oncology (ASCO) 
updated its guidance to recommend OS in all premenopausal women who would be considered 
for adjuvant chemotherapy because of high risk features [114]. 
 
1.7.4   Aromatase  Inhibitors  
Aromatase, a product of the CYP19 gene, is a cytochrome P450 enzyme. The third-generation 
aromatase inhibitors are those currently utilised in clinical practice today, and include 
anastrozole (Arimidex), letrozole (Femara) and exemestane (Aromasin), all administered in a 
once daily oral preparation. Anastrozole and letrozole are non-steroidal and bind reversibly to 
the heme group of the aromatase enzyme at their triazole group. Exemestane is an aromatase 
inactivator, a steroidal androgen substrate analogue that binds competitively and irreversibly 
to aromatase [115]. All 3 drugs can supress whole body aromatisation in vivo in the order of 
97-99%, corresponding to reduced levels of circulating oestrone, oestradiol and oestrone 
sulphate of 81-95%, 85-92% and 93-98% respectively [116, 117].  
 
1.7.4.1   Aromatase  Inhibitors  in  metastatic  disease  
Aromatase inhibitors (AIs) are superior to tamoxifen as first line therapy for postmenopausal 
women with ER+ breast cancer. This was first established in the metastatic setting via three 
key multicentre double blinded randomised controlled trials. Letrozole was significantly 
superior to tamoxifen in delaying time to progression in 907 patients (41 vs 26 weeks), time 
to treatment failure (40 vs 25 weeks) and objective response rate (30% vs 20%) respectively 
[118]. A further study found anastrozole superior to tamoxifen in time to progression (11.1 vs 
5.6 months) with clinical benefit seen in 59% of patients with anastrozole compared to 46% 
of those with tamoxifen in 353 patients. They also demonstrated fewer adverse events with 
anastrozole compared to tamoxifen (4.1% vs 8.2% thromboembolism; 1.2% vs 3.8% vaginal 
bleeding) [119]. A further trial comparing anastrozole with tamoxifen in 668 women, found 
the drugs were comparable, but anastrozole not superior to tamoxifen, with median time to 
progression of 8.2 months with anastrozole vs 8.3 months with tamoxifen. They also found 
both drugs comparable in objective response (32.9% of patients with anastrozole vs 32.6% of 
those with tamoxifen). Similarly they demonstrated lower adverse events with anastrozole 
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compared to tamoxifen (4.8% vs 7.3% thromboembolism, and 1.2% vs 2.4% vaginal bleeding 
respectively) [120] and therefore recommended use of anastrozole over tamoxifen. The reason 
this study failed to confirm superiority of aromatase inhibitors over tamoxifen as the others 
did is unclear. There was a higher proportion of patients with unknown ER status included 
however, and retrospective subgroup analysis of those known to be ER+ showed trends in 
favour of anastrozole over tamoxifen.  
 
1.7.4.2     Aromatase  Inhibitors  in  adjuvant  setting  
In the adjuvant setting, the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial 
established anastrozole as superior to tamoxifen in 9,366 women with early breast cancer. 
Disease free survival was significantly prolonged at 68 months (575 events with anastrozole, 
651 with tamoxifen, hazard ratio 0.87, 95% CI 0.78-0.97, p=0.01), as was time to recurrence 
(402 events vs 498 events, HR 0.79, 95% CI 0.70-0.90, p=0.0005) [121, 122]. Distant 
metastases and contralateral breast cancers were also significantly reduced. The combination 
arm was discontinued due to non-superiority over tamoxifen alone.  
 
Similarly the Breast International Group (BIG) 1-98 trial confirmed superiority of 5 years of 
adjuvant letrozole over tamoxifen with an 18% reduction in risk of an event (HR 0.82; 95% 
CI 0.71-0.95, p=0.007) [123, 124]. 
 
MA-17 was a double-blind randomised controlled trial of 1,918 women who had completed 5 
years of an adjuvant aromatase inhibitor, comparing 5 further years of letrozole vs placebo. 
Disease free survival was superior in patients receiving 10 years of AI, over 5 years AI plus 5 
years placebo (HR 0.66, 95% CI 0.48-0.91, p=0.01) [125]. There was no difference in overall 
survival however and it is worth noting 80% of these patients had also had prior tamoxifen 
before starting AI; most of them for duration of 4.5-6 years.  
 
A further approach is a sequence of adjuvant tamoxifen switching to an aromatase inhibitor 
after 2-3 years of treatment. The ideal sequence and duration is still debated. A large trial of 
4,742 patients confirmed superiority, across all events, of 2 years tamoxifen switched to 
exemestane, over 5 years tamoxifen alone (HR 0.68, 95% CI 0.56-0.82, p<0.001), although 
no significant difference in overall survival was found [126].  Similarly, in 5,187 women 
treated with adjuvant tamoxifen for 5 years, a switch to letrozole at that point improved disease 
free survival over placebo (93% vs 87%, p<0.001) [127]. A switch to anastrozole after 
completion of two years of tamoxifen is also associated with improved progression free 
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survival with a 40% reduction in events over continuing tamoxifen for five years of endocrine 
therapy [128]. The adjuvant tamoxifen and exemestane in early breast cancer (TEAM) trial 
demonstrated superiority of 2-3 years tamoxifen switched to exemestane over tamoxifen 
alone, and comparable results of the switch approach to 5 years of monotherapy with 
exemestane, suggesting both switch and monotherapy approaches are reasonable treatment 
options [129]. 
 
The benefit of AIs over tamoxifen in postmenopausal ER+ women is well established. 
However, interestingly this has not translated into improved overall breast cancer specific 
survival [130, 131]. AIs generally are better tolerated than tamoxifen with fewer 
gynaecological side effects, however the incidence of fractures, arthralgia and osteoporosis 
are increased [132]. 
 
1.7.4.3   Aromatase  Inhibitors  in  neo-­adjuvant  setting  
A meta-analysis of four trials including 1,160 patients confirmed superiority of neoadjuvant 
AIs over tamoxifen in postmenopausal women, with increased clinical objective response rate 
(RR 1.29; 95% CI 1.14-1.47, p<0.001) and increased breast conserving surgery rate (RR 1.36; 
95% CI 1.16-1.59, p<0.001) [133].  
 
The P024 trial confirmed superiority of 4 months of neoadjuvant letrozole over tamoxifen with 
overall response rates of 55% and 36% respectively (p<0.001); and increased rate of breast 
conservation surgery (45% vs 35%, p=0.022) [134]. Letrozole also correlated with a greater 
reduction in mean Ki67 (87% in letrozole, 75% with tamoxifen) [135]. Letrozole has also been 
demonstrated as an effective primary endocrine therapy in elderly patients [136].  
 
The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen 
(IMPACT) trial compared neoadjuvant tamoxifen, anastrozole or both for 3 months and found 
no significant difference in objective response rates between the groups but did demonstrate 
increased rate of breast conservation in the anastrozole group over tamoxifen group (46% vs 
22%, p=0.03) [137]. In the Preoperative Anastrozole Compared with Tamoxifen (PROACT) 
trial, 3 months of neoadjuvant anastrozole and tamoxifen yielded similar response rates by 
caliper and ultrasound measures. This trial included patients undergoing neoadjuvant 
chemotherapy; and when excluding these a trend to improved response was seen with 
anastrozole (36.2% vs 26.5%, p=0.09) [138].  
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Similar to letrozole and anastrozole, exemestane is superior to tamoxifen in the neoadjuvant 
setting with improved clinical response rate (76% vs 40%, p=0.05) and increased breast 
conservation rate (36.8% vs 20%, p=0.05) [139].  
 
The American College of Surgeons Oncology Group (ACOSOG) Z1031 compared the three 
third generation AIs for 16-18 weeks of neoadjuvant treatment and found no significant 
differences between anastrozole, letrozole and exemestane treated groups. Rates of breast 
conservation were improved with all AIs with no one drug being superior [140]. Similar rates 
of down regulation of ER, PR and reduced Ki67 have also been shown with short course (14 
days) of anastrozole and letrozole with no significant difference between these drugs [141].  
 
Most of the trials of neoadjuvant endocrine therapy have treated patients for a duration of 3-6 
months. Prolonging neoadjuvant letrozole has also been shown to increase response rates with 
breast conservation increasing from 60% to 72% in women who continued treatment for longer 
than 3 months [142], supporting a longer treatment period. 
 
1.7.4.3.1   Neoadjuvant  endocrine  therapy  vs  chemotherapy  
Comparisons of neoadjuvant chemo and endocrine therapy are limited reflecting the fact that 
neoadjuvant chemotherapy is less effective in ER+ disease than ER- in achieving pathological 
complete response (8% in ER+ cancers compared to 24% of ER-, p<0.001) [143]. The 
Neoadjuvant Endocrine vs Chemotherapy Trial (NEOCENT) was designed to answer this 
question, however the trial closed early due to slow recruitment therefore no significant 
conclusions can be drawn [144]. 
 
1.8   Molecular  changes  in  response  to  neoadjuvant  aromatase  inhibition  
Miller et al investigated changes in gene expression profiles in response to 14 days of 
neoadjuvant letrozole in 58 patients, and found consistent changes in 143 genes. 91 down-
regulated genes were involved in proliferation, cell cycle progression and mitosis (including 
CDC2, cyclins B1 and B2, CKS2), and oestrogen related (including KIAA0101, TFF1, TFF3, 
IGFR1). Up-regulated genes were involved in connective tissue extracellular matrix (including 
COL1A1, COL1A2, MMP2, DCN), immune response and inflammation (ILIR1, COLEC12, 
TNFSF10), and cell adhesion (CD36, CDH111, ITGB2, SRP, SPON1, DPT) [145].  
 
Mackay et al conducted a similar study comparing the effect of 2 weeks preoperative 
anastrozole and letrozole in 34 patients, and found very similar changes, with down-regulation 
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of oestrogen related and proliferation genes, and up-regulation of extracellular matrix 
remodelling genes, including collagens and small leucine-rich proteoglycan family members. 
Similar changes were seen in response to both letrozole and anastrozole. They derived the 
Global Index of Dependence on oEstrogen (GIDE), from the number of genes with greater 
than two fold change between baseline and 14 days, which correlated strongly with change in 
Ki67 in response to treatment and negatively with ERBB2 expression [146]. 
 
A further study by Miller, identified 205 co-variables, (69 at baseline, 45 at day 14, and 91 
changed between baseline and day 14) which could differentiate between responsive and non-
responsive tumours after 14 days of neoadjuvant letrozole [147]. In subsequent work, they 
were unable however to define consistent changes in gene expression in tumours non-
responsive to neoadjuvant letrozole with some demonstrating similar down regulation of 
oestrogen related and proliferation associated genes as responsive tumours. This highlights the 
inherent heterogeneity of endocrine resistance in breast cancers [148]. 
 
Response to neoadjuvant endocrine therapy can be assessed clinically, with calipers, and 
surgeon opinion of achieving breast conservation; or radiologically with mammography, 
ultrasound or MRI measurements. As molecular changes are apparent after only 10-14 days 
of treatment [148] this presents an opportunity to identify features of response or resistance 
much earlier than would be apparent clinically [147, 149]. Sequential biopsy allows measures 
of molecular markers on treatment, including Ki67 [150], which can predict response to 
neoadjuvant endocrine therapy [151]. This equally correlates to long term outcome, as was 
first demonstrated in the IMPACT study, where 2 week on treatment Ki67 was predictive of 
recurrence free survival at median 37 months; Ki67>10%, 9 of 35 events (26%), Ki67<10% 
13 of 118 events (11%), p=0.008 [137, 152]. This was also validated in the ATAC cohort [121, 
122].  
 
In estimating prognosis, numerous clinicopathological and biomarker studies have emerged. 
The opportunity to take sequential biopsies from the same tumour over time in response to 
treatment, has also heralded predictive biomarker studies (see section 1.9.3).  
 
1.9   Prognostic  and  predictive  factors  
Clinical decision making in breast cancer requires robust and personalised stratification in 
order that patients are given appropriate drugs and spared from potentially toxic over-
treatment that would offer little benefit [153]. In doing this we must identify markers of 
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prognosis, that is a measurable characteristic which provides likely outcome in a non-treated 
individual, to ensure those with higher risk disease are offered appropriate systemic therapies 
[154]. Predictive markers identify those who would likely benefit from a particular treatment, 
in terms of disease response or overall survival [155]; the most common in breast cancer being 
ER, expression of which is predictive of benefit from endocrine therapy. HER2 is both a 
marker of poorer prognosis and predictive of response to anti-HER2 targeted therapy. The 
classic clinicopathological prognostic and predictive features are discussed earlier in section 
1.3. Further methods using clinicopathological features to guide clinical decisions are 
discussed below.  
 
1.9.1   Clinicopathological  prognostic  estimates  
1.9.1.1   Nottingham  Prognostic  Index  
Nottingham Prognostic Index (NPI) is a numerical value calculated from tumour size, lymph 
node staging and tumour grade [156] into one of six prognostic groups; excellent, good, 
moderate I, moderate II, poor and very poor corresponding to increasing number [157]. NPI 
correlates well with long term outcome at 10-15 years [158], has been independently validated 
[159], and is easily reproducible with no added cost to standard measured pathology variables. 
The ability to identify high risk disease is comparable to gene expression profiling [160], 
however it does not take any account of tumour biology, therefore would not identify poor 
prognosis subgroups, such as small sized basal-like tumours [161] or HER2+ tumours. 
Attempts to combine IHC biomarkers with NPI have improved on this [162, 163] but 
undoubtedly could be further refined. 
 
1.9.1.2   Adjuvant!  Online  
Adjuvant! Online (AO) predicts prognosis and likely net benefit of endocrine and 
chemotherapy [164], based on patient demographics and clinicopathological tumour features, 
calculated by actuarial analysis of multiple epidemiological and outcome data. AO has been 
demonstrated as effective as NPI for assigning prognostic group [165, 166], however is not 
reliable in the elderly, where it overestimates disease free and overall survival [167], or in 
BRCA1 mutation carriers where it underestimates risk [168]. 
 
1.9.1.3   St  Gallen  Consensus  Guidelines  
In 2015 the St Gallen Consensus Conference expert panel agreed that molecular subtype can 
be determined on basis of IHC rather than RNA profiling or multigene classifiers [169] (see 
section 1.9.2) as follows:  
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luminal A:  ER+ / PR+ / HER2- / Ki67 low, 
luminal B:  ER+ / PR+ / HER2- / Ki67 high   or   ER+ / PR+ / HER2+, 
triple negative:  ER- / PR- / HER2-  and  
HER2 enriched:  ER- / PR- / HER2+.  
The panel agreed that determination of subtype was necessary for treatment planning, however 
it was split on advising whether Ki67 or multi-gene assaying was always required in deciding 
to use chemotherapy in ER+ HER2- patients.  
 
1.9.1.4   IHC4  
IHC4 uses a formula incorporating IHC measures of ER, PR, HER2 and Ki67 to calculate an 
IHC4 score which correlates to prognosis [170]. IHC4 provides valuable additional prognostic 
information combined with standard clinicopathological measures. However in node negative, 
HER2 negative subgroups, it is inferior to gene assays, including PAM50 and Oncotype Dx 
[171] (see section 1.9.2). 
 
1.9.1.5   Preoperative  endocrine  prognostic  index  
The Preoperative Endocrine Prognostic Index (PEPI) for recurrence free survival was 
developed from the P024 trial and validated in the IMPACT cohort. PEPI is calculated from 
tumour size, nodal stage, ER and Ki67 of the surgical specimen following neoadjuvant 
endocrine treatment, giving a score of 0 (good prognosis), 1-3 (intermediate) and 4+ (poor 
prognosis) which correlated to recurrence free survival (log rank p=0.002) [172]. PEPI 0 
patients with early stage tumours had no recurrence events in 5 years in the training cohort, 
highlighting an excellent prognostic group who could forego adjuvant chemotherapy.  
 
1.9.2   Prognostic  gene  signatures    
1.9.2.1   Genomic  Grade  Index  
Genomic Grade Index (GGI) is a 97 gene assay which can characterise tumour grade into low 
or high risk, which is superior to the Elston and Ellis pathological grading 1-3, in predicting 
recurrence free survival [173]. 
 
1.9.2.2   Oncotype  Dx  
Oncotype Dx uses quantitative real time polymerase chain reaction (qRT-PCR) measures of 
21 genes (16 cancer related, 5 reference), to calculate a recurrence score which has been shown 
to correlate to survival, independent of age and tumour size, in node negative, tamoxifen 
treated ER+ breast cancer [174]. The recurrence score also predicts magnitude of 
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chemotherapy benefit in these patients. Those with a high score (>31) derive large benefit, and 
those with a low score (<18) derive minimal benefit only [175]. The Trial Assigning 
Individualised Options for Treatment (TAILORx) of 10,253 women, validated the use of a 
low recurrence score (revised to <10) to identify patients who could be spared chemotherapy 
but who would have been recommended to receive it based on clinicopathological features. 
Of the 1,626 patients with a low risk score, all were treated with adjuvant endocrine therapy, 
and only 88 events of recurrence or death occurred by 5 years [176]. More work is required to 
establish best management of women with an intermediate score (11-25).  
 
1.9.2.3   PAM50ROR  
PAM50 is another qRT-PCR assay, which employs 50 genes to categorise patients into one of 
the intrinsic molecular subtypes; luminal A, luminal B, HER2-enriched or basal, based on 
relative distance to the centroid of each subtype [177]. PAM50 combined with a ‘risk of 
recurrence’ (ROR) score, correlates to long term outcome and is also predictive of response to 
neoadjuvant chemotherapy. ROR is calculated using a formula which includes Pearson 
correlations to gene expression profiles of each of the intrinsic subtypes, combined with a 
proliferation score (mean expression of 18 gene sub-set of the PAM50 genes), and pathologic 
tumour size, producing a result ranging 0-100. ROR is prognostic independent of standard 
clinicopathological variables, however combination of both is overall superior [178] in 
predicting late distant recurrence after adjuvant endocrine therapy. ROR can identify low risk 
ER+ node negative tumours with >95% 10-year survival without chemotherapy; which is 
comparable to performance of Oncotype Dx [179]. PAM50ROR is available commercially as 
Prosigna.  
  
1.9.2.4   MammaPrint  
MammaPrint was developed from empirical microarray analysis of 78 breast cancer patients 
who were aged less than 55 years, with tumours 5cm diameter or less and node negative, who 
were deemed to have poor prognosis if they developed metastases within 5 years, and good 
prognosis if not. Supervised analysis of 25,000 genes identified 70 genes which could 
accurately predict prognosis. Genes involved in cell cycle, invasion and metastases, 
angiogenesis, and signal transduction were enriched in the poor prognostic profile, including 
cyclin E2, MCM6, MMP9, MMP1, RAB6B, ESM1 and VEGF receptor FLT1 [180]. The 70-
gene signature was subsequently validated in a larger cohort of 295 patients, where a poor 
prognosis signature corresponded to 10-year survival of 54.6% +/-4.4, compared with 94.5% 
+/-2.6 with the good prognosis signature. Similarly, recurrence free survival was 50.6% +/- 
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4.5, and 85.2% +/- 4.3, in poor and good prognostic groups respectively [181]. MammaPrint 
has been externally validated by other groups in both node negative [182] and node positive 
patients [183], including a subgroup of 101 patients with 1-3 positive lymph nodes, who did 
not receive chemotherapy, where Mammaprint was superior to Adjuvant! Online at predicting 
breast cancer specific survival. The poor prognostic signature is also predictive of patients 
who will derive benefit from adjuvant chemotherapy in addition to endocrine therapy [184].  
 
The microarRAy prognoSTics in breast cancER (RASTER) study prospectively assessed the 
feasibility of implementing MammaPrint into treatment. Risk as assessed by 
clinicopathological features, often differed from MammaPrint, with discordance in 37% with 
Adjuvant! Online, 39% with St Gallen guidelines, and 27% with Nottingham Prognostic 
Index; more often MammaPrint classifying as low risk, where clinicopathological features 
classified as high risk [185]. A follow up study at 5 years found in 219 MammaPrint low risk 
patients, disease free survival was 97%; and in 208 MammaPrint high risk was 91.7% 
(p=0.03). This is despite 15% (33/219) of low risk patients receiving adjuvant chemotherapy, 
vs 81% (169/208) of high risk patients [186], suggesting omission of chemotherapy in those 
with a low risk Mammaprint signature does not compromise outcome.  
 
Microarray In Node negative and 1-3 positive lymph node Disease may Avoid ChemoTherapy 
(MINDACT), is a randomised prospective trial of 6,693 women with invasive, early stage 
breast cancer, comparing the 70-gene signature with Adjuvant! Online in identifying patients 
unlikely to benefit from adjuvant chemotherapy. Patients with low risk disease both 
genomically and clinically, had no adjuvant chemotherapy; those deemed high risk by both 
genomic and clinical factors did have chemotherapy. Those with discrepancy between clinical 
and genomic risk were randomised to undergo chemotherapy or not. High-clinical low-
genomic risk patients, who did not receive chemotherapy (n=748), had a distant metastases 
free survival rate of 94.4% (95% CI 92.3-95.9) at 5 years. This is only 1.5 percent lower than 
the same risk patients (n=749) who did receive chemotherapy (95.9%, CI 94.0-97.2) [187]. 
Interestingly, of these high-clinical low-genomic risk patients, 48% had positive lymph nodes, 
93% grade 2-3 disease, and 34% were aged 50 years or younger; all factors traditionally 
considered poorly prognostic. In patients deemed high-clinical risk with one positive node 
(n=801), or two or three positive nodes (n=405); the 70-gene signature indicated low risk 
disease in 505 (63%) and 226 (55.8%) respectively. The study was however underpowered to 
determine benefit of chemotherapy in those with discordant clinical and genomic risk, and 
needs longer term follow up in due course.  
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1.9.2.5   Endopredict  /  EndopredictClin  
Endopredict (EP) combines three proliferation associated genes, five ER related genes and 
three housekeeping genes, assessed by qRT-PCR, to provide a score 0 to 15, to predict distant 
recurrence in endocrine treated ER+ HER2- patients [188]. EPclin combines EP with nodal 
status and tumour size into an algorithm to direct treatment decisions. EP and EPClin have 
been shown to provide significant prognostic information above that of Oncotype Dx in 928 
patients with ER+ disease treated with 5 years of endocrine therapy; especially in years 5-10 
of follow up and in patients node positive [189]. 
 
1.9.2.6   Breast  Cancer  Index  
Breast cancer index (BCI) combines two prognostic gene signatures: molecular grade index 
(MGI) and HOXB13:IL17BR (H:I) ratio, to estimate risk of recurrence in node negative ER+ 
patients. MGI is a five-gene prognostic signature which calculates a genomic grade, and 
improves on histological prognosis of grade 2 tumours by classifying them as ‘grade 1-like’ 
or ‘grade 3-like.’ H:I ratio is a two gene marker of risk of recurrence in ER+ breast cancer 
treated with tamoxifen [190]. The combination outperforms either two independently, and also 
better stratifies risk of recurrence within 10 years than standard clinicopathological variables. 
BCI categorises patients as low, intermediate or high risk; which correlates to 10-year 
recurrence free survival of 87.5%, 83.9% and 74.7% respectively, in a validation cohort of 
146 patients with ER+ disease, across both lymph node negative and positive subgroups [191].  
 
1.9.3   Predictive  Gene  signatures  
The Sensitivity to Endocrine Therapy (SET) Index was derived from a cohort of 437 ER+ 
cancers and is based on expression of ESR1-related genes, 106 with positive correlation and 
59 with negative correlation. It categorises into high, intermediate and low risk groups which 
correlate to recurrence free and overall survival at 10 years in tamoxifen treated patients, but 
not in non-treated; suggesting it is predictive of response to tamoxifen [192]. Lymph node 
status was however also independently prognostic in the training cohort.   
 
The ACOSOG Z1031B study comparing neoadjuvant letrozole, anastrozole and exemestane, 
assessed an on-treatment biopsy after 2-4 weeks. If Ki67 was >10% patients were deemed to 
be non-responsive to AI and switched to neoadjuvant chemotherapy or proceeded to surgery. 
49 of 236 (20.7%) women had Ki67>10% at 2 weeks, of these 35 switched to chemotherapy, 
and pathological complete response was achieved in 2 patients. At 4.4 years follow up they 
also had a significantly increased risk of relapsed disease (log rank p=0.004) [193]. Gene 
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expression assessed by MultiGene Proliferation Score (MGPS) RNA assay demonstrated even 
in those with Ki67>10% at 2 weeks, the non-responders, there was still down regulation of 
MGPS, although to a lesser degree than in those with Ki67 <10%.  One limitation of this study 
is the use of pCR to assess response to chemotherapy in ER+ tumours, which may explain the 
low rate demonstrated. Further survival data is also awaited.  
 
A 4-gene signature, able to predict response to neoadjuvant AI based on expression of two 
genes pretreatment, namely IL6ST (associated with immune signaling) and 
NGFRAP1(apoptosis induction related), and two proliferation genes (ASPM and MCM4) after 
two weeks of letrozole, has been identified. This model has a 96% accuracy (96% sensitivity, 
94% specificity; positive predictive value 98%, negative predictive value 89%) [149]. Blinded 
independent validation in a second cohort treated with neoadjuvant anastrozole yielded similar 
results, predicting response correctly in 40 of 44 patients; 91% accuracy, 90% sensitivity, 92% 
specificity. The 4-gene signature also correlates with progression free and breast cancer 
specific survival in the training cohort and can be assessed by qRT-PCR and/or IHC.  
 
These studies confirm the added value of an on-treatment biopsy in predicting response to 
neoadjuvant endocrine therapy, and indeed long term outcome. There are several other 
ongoing trials looking to prospectively explore this further, using on-treatment biopsy 
assessment of response to alter decisions about ongoing treatment. 
 
The trial of Peri-Operative Endocrine Therapy: Individualising Care (POETIC) is a phase III 
randomised prospective multicentre trial which recruited 4,486 patients over 5 years, 
comparing 4-weeks perioperative AI (2 weeks pre- and 2 weeks post-operative) with no 
therapy. The primary endpoint is to assess outcome in the perioperative AI group over surgery 
followed by standard adjuvant therapy group. A secondary outcome is to determine the most 
effective time points for molecular profiling, comparing measures of Ki-67 at baseline and at 
2 weeks, in prediction of recurrence free and overall survival [194]. Recruitment closed in 
2014 and patients are being followed up annually for 10 years.  
 
The ALTERNATE trial is a further prospective trial currently recruiting to compare 
neoadjuvant anastrozole or fulvestrant or combination of both, for 6 months. After 4-weeks, 
Ki67 will be assessed, and patients switched to neoadjuvant chemotherapy if >10%. Patients 
will continue the same endocrine drug for adjuvant therapy and PEPI will also be assessed. 
The primary objective is to determine whether endocrine resistance is less with fulvestrant, or 
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fulvestrant plus anastrozole, than anastrozole alone. Secondary aims will examine degree of 
Ki67 suppression amongst others [195]. 
 
The NeoMONARCH phase II randomised multicentre study of 224 patients compared 
abemaciclib (CDK4/6 inhibitor, see section 1.10.5) alone, abemaciclib plus anastrozole, or 
anastrozole alone for 2 weeks preoperatively. Ki67 assessed at baseline and again at 2-week 
biopsy, was significantly more supressed at a 9-month interim analysis with abemaciclib either 
as monotherapy or in combination (p<0.001, n=64) than with anastrozole alone [196]. Again, 
we await survival outcomes in these patients.   
  
Most of the above described prognostic gene signatures and clinicopathological criteria aim 
to distinguish ER+ patients with favourable prognosis from those with adverse prognosis. In 
HER2+ and TNBC treatment options are not so debated. Uncertainty arises in luminal disease, 
and particularly where it is safe to omit adjuvant chemotherapy to avoid overtreatment and its 
associated toxicities. Tumour biology and prognosis at genomic and transcriptomic level does 
not always correlate with traditional clinicopathological features. Indeed, many studies have 
alluded to the fact that combining biomarkers with clinical features may provide the most 
useful prognostic information [178, 179, 189], but there is by no means an adopted standard 
as yet. 
  
1.10   Endocrine  resistance  
Although 70% of all breast cancers express ER, resistance to endocrine therapies is common. 
This can be de novo or intrinsic resistance present from the outset of disease, or it can be 
acquired in response to treatment, where a tumour initially responsive to treatment then 
progresses or recurs later. Response in the neoadjuvant setting is around 70% [147], however 
in the adjuvant setting up to 50% of patients will eventually develop resistance to one or more 
drugs [197]. The mechanisms of resistance are multiple. There is tumour heterogeneity in 
breast cancer, and tumours with a small number of ER+ cells amongst predominantly ER- 
cells have poorer and shorter response to endocrine treatment [198]. In such cases ER- clones 
would dominate over time and these tumours may exhibit de novo resistance despite 
containing some responsive cells, as the clinically appreciable change in the tumour would be 
negligible. Loss of ER expression, where a cancer initially all ER+ becomes ER- is one 
mechanism in a small number of patients, around 10% [172]. The majority however remain 
ER+ despite no longer responding to endocrine therapies, suggesting the tumour is able to 
progress independently of a functioning activated ER. Partial response to second or third line 
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agents is seen in those who retain ER expression [199]. This may be driven by cross talk 
between ER and alternative growth factors, most commonly the receptor tyrosine kinase 
human epidermal growth factor receptors (EGFR), HER1, HER2, HER3 and HER4. ER 
independent activation of the receptor and its subsequent downstream signalling is also 
causative.   
 
Defining primary and acquired resistance has been problematic. Adjuvant endocrine therapy 
is given to ER+ disease in the hope of preventing micrometastatic disease causing a relapse. 
Patients who have an early relapse are likely to have primary endocrine resistance, however 
those who relapse later may still have endocrine sensitivity, and therefore may benefit from 
further ER+ targeted drugs, despite previous endocrine therapies. The Advanced Breast 
Cancer (ABC3) consensus group has recently therefore proposed definitions as follows:  
Primary resistance – relapse within first two years of adjuvant endocrine therapy, or 
progressive disease within first 6 months of first line endocrine therapy in metastatic breast 
cancer.  
Acquired resistance – relapse whilst on adjuvant endocrine therapy but after first two years, 
or relapse within twelve months of completing adjuvant endocrine therapy; or progressive 
disease more than 6 months after initiating endocrine therapy for metastatic breast cancer, 
whilst on endocrine therapy [200]. 
 
Mechanisms of endocrine resistance are multiple and complex, and may relate to host factors 
affecting bioavailability and drug adherence, and also molecular mechanisms affecting the 
tumour microenvironment and the tumour cell and oncogenic signalling [201]. Herein are 
discussed the most common mechanisms of endocrine resistance, and current and emerging 
targeted drug therapies against them, summarised figure 1-7.  
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Figure  1-­7.  Mechanisms  of  endocrine  resistance  and  endocrine  therapy  targets  
Schematic   diagram   of   receptors   and   pathways   commonly   involved   in   endocrine  
resistance,  adapted  from  Selli  et  al  2016  [202].  
Current  and  novel  drugs  in  orange  squares  
CDK  -­  cyclin  dependent  kinase,  EGFR  -­  epidermal  growth  factor  receptor,    
FGFR  -­  fibroblast  growth  factor  receptor,  HDAC  -­    histone  deacetylase  i  -­   inhibitor,  
IGFR  -­  insulin-­like  growth  factor  receptor,  MAPK  -­  mitogen  activated  protein  kinase,  
mTOR  -­  mammalian  target  of  rapamycin,  PI3K  -­  phosphatidylinositol-­3kinase,    
PTEN  –  phosphatase  and  tensin  homolog  
 
1.10.1   ER  and  Growth  Factors  
Multiple receptor tyrosine kinases (RTKs) including the EGFRs [203], fibroblast growth 
factor receptors (FGFR) [204] and insulin-like growth factor receptors (IGFR) [205] have been 
implicated in endocrine resistance, by ligand independent activation of ER. This may be 
achieved by downstream signalling through different kinase pathways including PI3K and 
MAPK [206] that can activate ER proteins by phosphorylation.  
 
In ER+ cell lines increased levels of EGFR and HER2 have been demonstrated at time of 
tamoxifen resistance [206]. This led to several studies assessing the effect of dual blockade of 
EGFR plus ER, regardless of HER2 expression, although these have failed to show any 
advantage of this approach. Gefitinib, an EGFR inhibitor, combined with tamoxifen had no 
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significant advantage in PFS over placebo in ER+ metastatic disease [207]. Ganitumab, a 
monoclonal IGF-1R antibody, in addition to endocrine therapy did not improve outcome in 
locally advanced and metastatic ER+ breast cancer [208]. Lapatinib combined with letrozole 
failed to improve PFS in ER+HER2- metastatic patients [209]. It seems reasonable to conclude 
that targeting growth factor receptors when it is unknown which one is driving the process of 
endocrine resistance is ineffective.  
 
1.10.1.1  ER  and  HER2  
ER+HER2+ tumours account for around 10% of all breast cancers, and are less responsive to 
endocrine therapy than ER+HER2- tumours [210] [211]. Dual targeting of ER and HER2 has 
been effective. In metastatic ER+HER2+ breast cancer the addition of trastuzumab to 
anastrozole improved progression free survival (PFS) from 2.4 to 4.8 months compared with 
anastrozole alone [212]. Also in the metastatic setting, the combination of letrozole and 
trastuzumab was shown to produce a sustained clinical benefit of at least 1 year in most 
patients [213]. Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2, given in 
addition to letrozole increased PFS from 3 to 8.2 months compared with placebo in metastatic 
ER+HER2+ patients [214].  
 
1.10.2   Oncogenic  pathway  activation  
The phosphatidylinositol 3-kinase (PI3K) / AKT / mTOR pathway is an oncogenic signalling 
pathway frequently implicated in endocrine resistant breast cancer, (see also section 3.1). PI3K 
can be activated by growth factor receptor tyrosine kinases and G-protein coupled receptors. 
Mutation or amplification of the genes encoding the PI3K catalytic subunits, p110α (PIK3CA) 
and p110β (PIK3CB), also cause activation. PI3K phosphorylates phosphatidylinositol 4,5-
bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3) which recruits proteins 
including AKT and PDK1 to the plasma membrane, driving cell cycle survival and progression 
on activation [215]. AKT activates the mammalian target of rapamycin (mTOR)-containing 
complex 1 (TORC1) which regulates protein synthesis. Inhibition of the PI3K pathway is 
maintained by the lipid phosphatases, phosphatase and tensin homolog (PTEN) and INPP4B, 
which dephosphorylate PIP3 and PIP2 respectively [216]. 
 
Pre-clinical studies demonstrate enhanced anti-tumour effects with dual blockade of ER and 
PI3K pathways, which lead to the development of a trial of 4 months neoadjuvant letrozole 
plus everolimus, an mTOR inhibitor, versus letrozole plus placebo in 270 postmenopausal 
women with ER+ early breast cancer. Clinical response was higher in the everolimus arm 
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(68.1% vs 59.1%, p=0.62) as was reduction in Ki67 (57% vs 30%, p<0.01) [217]. The Breast 
Cancer Trials of Oral Everolimus-2 (BOLERO2) has confirmed benefit of this dual approach 
in metastatic ER+ disease, where everolimus restores sensitivity to exemestane in progressive 
disease. In 726 women, progression free survival increased to 6.9 months in exemestane plus 
everolimus, versus 2.8 months in exemestane plus placebo (HR 0.43, 95% CI 0.35-0.54, 
p<0.001) [218].  
 
The role of pan-PI3K inhibitors, such as buparlisib, is also being explored. The BELLE-2 trial 
of 1,147 patients with metastatic AI resistant ER+ disease, found median progression free 
survival was 6.9 months with fulvestrant and buparlisib, versus 5 months with fulvestrant plus 
placebo (HR 0.78, p<0.001). Adverse events were also much more common in the 
combination group however (77.3% vs 32%) with consequent increased discontinuation rates 
(13.2% vs 1.8%). PFS was more enhanced in those with PIK3CA mutations in their archived 
original tumour with fulvestrant and buparlisib over fulvestrant and placebo (6.8 months vs 4 
months, HR 0.76, p=0.14). 200 patients were found to have a PIK3CA mutation in circulating 
tumour DNA at enrolment and in this subgroup, median PFS was improved further than the 
overall cohort with buparlisib over placebo (7 months vs 3.2 months, HR 0.54, p<0.001) [219]. 
Full survival outcomes from this trial have not yet been reported.  
 
The Mitogen Activated Kinase Pathway (MAPK) is a further signalling pathway that is 
activated by growth factor receptors and has been implicated in endocrine resistance. MAPK 
is stimulated by the RAF serine/threonine kinase and activates additional downstream kinases 
such as ERK, c-Jun and p38MAPKs which phosphorylate downstream transcription factors 
[201]. Trials dual targeting ER and MAPK are ongoing now. A phase II trial of fulvestrant 
alone or in combination with AZD6244, a MAPK inhibitor, in metastatic AI resistant ER+ 
cancer finished recruiting in September 2016 [clinicaltrials.gov NCT01160718].  
 
1.10.3   ESR1  mutations  
Mutations in the ESR1 gene encoding ERα are present in 21% of metastatic ER+ breast cancers 
[220]. Mutations cluster in a small region encoding the ligand binding domain, most 
commonly at amino acids 537 and 538, causing ligand independent activation of ER with 
promotion of ER dependent genes in vitro [221]. Toy et al confirmed a mutation was present 
in 9 of 36 (25%) metastatic tumours. Two matched primary samples from diagnosis were 
available, neither of which had ESR1 mutation. Using the BOLERO2 cohort of endocrine 
resistant metastatic breast cancers, ESR1 mutations were found in 5 of 44 (11%) tumours; with 
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only 6 of 138 (3%) having ESR1 mutations at diagnosis. Further, Robinson et al described 6 
of 11 (54.5%) metastatic endocrine treated patients with ESR1 mutations, with matched 
diagnostic samples from 3 revealing no ESR1 mutations [222]. In 962 samples at diagnosis in 
The Cancer Genome Atlas Network, ESR1 mutations were only present in 0.5% [67]. Given 
most metastatic ER+ patients will have received endocrine therapy, we can assume ESR1 
mutation is acquired over time and in response to endocrine therapy. This contrasts with the 
frequency of other common breast cancer genomic alterations, with comparable rates in 
primary and metastases of TP53, CCND1, MCL1, MYC, FGFR1 [223] and PIK3CA, see also 
chapter 3. Jeselsohn described ESR1 mutations in 9 of 76 (12%) metastatic ER+ tumours; but 
this increased to 5 of 25 (20%) when selecting patients who had received multiple lines of 
prior endocrine therapy [223]. In the PALOMA3 trial (see section 1.10.5) ESR1 mutations 
were found in 91 of 360 (25.3%) patients. In multivariate analysis, ESR1 mutations were 
associated with previous aromatase inhibitor use (rather than tamoxifen), sensitivity to prior 
endocrine therapy, and bony or visceral metastases [224]. The Study of Faslodex with or 
without concomitant Arimidex vs Exemestane following progression on non-steroidal 
Aromatase inhibitors (SoFEA) trial, compared fulvestrant plus anastrozole, fulvestrant plus 
placebo, and exemestane in 723 ER+ patients with advanced or metastatic disease who had 
progressed or relapsed on a non-steroidal AI. Overall there were no significant differences in 
treatment arms in progression free or overall survival [225], however in retrospective analysis 
they identified ESR1 mutations in 63 of 161 (39.1%) patients. In this subgroup was a 
significantly superior effect of fulvestrant over exemestane; with progression free survival 5.7-
months (95% CI 3.0-8.5) vs 2.6 months (95% CI 2.4 – 6.2); (HR 0.52, 95% CI 0.30-0.92; 
p=0.02) [226]. 
 
1.10.4   ER  co-­regulators  
Co-regulators are proteins that bind to ER and modify its effectiveness in controlling gene 
expression; by increasing (coactivators) or reducing (corepressors) its activity. Coactivators 
including AIB1 and MNAR/PELP1 [201] can become amplified causing hyperstimulation of 
ER leading to tumourigenesis and cancer progression. Corepressors including N-COR and 
SMRT, which decrease ER function, have also been implicated in endocrine resistance [86]. 
Another mechanism of facilitating transcription factor interaction with chromatin is through 
pioneer factors, transcription factors which directly bind to condensed chromatin 
independently of other proteins and can modulate chromatin structures. Pioneer factors recruit 
other transcription factors and histone modification enzymes, controlling DNA methylation. 
Forkhead protein (FOXA1) [227], TLE proteins, AP2Y and PBX1 have been proposed as 
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pioneer factors in breast cancer [228]. Pioneer factors do not require additional transcription 
factors therefore allow quick interaction between transcription factors and chromatin, resulting 
in rapid transcription.  
 
1.10.5   Cell  cycle  signalling  
Endocrine therapy leads to G1/S phase cell cycle arrest. Cyclins are crucial to cell cycle 
progression, and aberrant regulation of positive and negative regulators of the cell cycle, 
including MYC, cyclins-D1 and E1, p21 and p27 have been implicated in endocrine resistance 
[229]. Expression of cyclin-D1 is higher in luminal tumours than in other subtypes, 
particularly luminal B, whereas cyclins-B1 and E1 are more common in basal tumours [230]. 
Increased expression of cyclin-D1 is achieved as a direct transcription factor of ER, or by 
amplification of CCND1, or by mitogenic signalling pathways. Cyclin-D1 binds to cyclin 
dependent kinases 4 and 6 (CDK4/6) which partially phosphorylates the retinoblastoma (RB) 
tumour suppressor protein, losing its inhibitory function and activating S-phase transcription 
genes (including cyclin-E and CDK2) driving cell cycle progression [231].  
 
CDK4/6 inhibitor drugs, such as palbociclib and ribociclib, have proven highly effective in 
prolonging benefit from endocrine therapy. The Mammary Oncology Assessment of 
LEE011’s (Ribociclib’s) Efficacy and Safety (MONALEESA-2) trial assessed ribociclib plus 
letrozole against placebo plus letrozole in 668 patients with advanced ER+ HER2- breast 
cancers with no prior endocrine therapy (except non-steroidal AI completed >12 months prior 
to recurrence). Ribociclib was significantly superior to placebo in median progression free 
survival, and in fact was not yet reached by the time of interim reporting (95% CI 19.3 months 
– not reached, vs 14.7 months, 95% CI 13-16.5) [232]. 
 
The PALbociclib: Ongoing trials in MAnagement of breast cancer (PALOMA)-2 trial 
compared letrozole plus palbociclib with letrozole plus placebo in 666 women with ER+ 
HER2- metastatic breast cancer. Progression free survival was significantly improved with 
palbociclib; 24.8 months (95% CI 22.1 months – not estimable) vs 14.5 months (12.9-17.1), 
(HR 0.58, 95% CI 0.46-0.72, p<0.001) [233]. 
 
The PALOMA3 trial assessed fulvestrant plus palbociclib over fulvestrant plus placebo, in 
521 patients with metastatic ER+ breast cancer; all of whom had between one and three 
previous endocrine therapies. Progression free survival was significantly improved with 
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palbociclib; 9.5 months (95% CI 9.2-11.0) vs 4.6 months (3.5-5.6) (HR 0.46, 95% CI 0.36-
0.59, p<0.0001) [224].  
 
Toxicity, particularly neutropenia, is problematic with CDK4/6 inhibitors however, occurring 
in 66.4% of patients with ribociclib and 1.4% of placebo in MONALEESA2. In PALOMA3 
80% of patients experienced neutropenia, and 54% had to have dosing interruptions 
consequently. The effect on overall survival is still to be established with CDK4/6 inhibitors 
also.  
 
1.10.6   Epigenetics  
Epigenetics refers to the reversible modification of DNA and gene expression without altering 
DNA sequence. DNA methylation, histone modification and nucleosome remodelling are 
major epigenetic mechanisms in breast cancer. DNA methyltransferases (DNMTs) interact 
with histone deacetylases (HDACs) and the methyl-CpG-binding domain (MBD) proteins to 
mediate DNA methylation. Epigenetic silencing of ER regulated genes and ESR1 itself have 
been implicated in endocrine resistance [234]. The Cancer Genome Atlas identified five 
methylation subgroups with over 4,000 differentially methylated genes. One hypermethylated 
phenotype was significantly enriched with luminal B mRNA subtype tumours [67].  
 
A small phase II trial of 43 patients found Vorinostat, a HDAC inhibitor, combined with 
tamoxifen was well tolerated in ER+ metastatic breast cancer patients who had disease 
progression on endocrine therapy. Clinical benefit, defined as response or static disease >24 
weeks, was achieved in 40% [235]. Entinostat another HDAC inhibitor, was assessed in a 
phase II trial of 130 women with progressive disease on non-steroidal AI. Exemestane plus 
entinostat improved PFS to 4.3 months vs 2.3 months with exemestane plus placebo (HR 0.73, 
95% CI 0.5-1.07, p=0.055) [236]. Luminal B tumours may benefit more from epigenetic drug 
targeting, given the higher frequency of methylation in this subtype.   
 
1.10.7   Tumour  heterogeneity  
Breast cancer is inherently heterogeneous, a feature which enhances metastatic potential and 
resistance to drug therapies. Heterogeneity is regulated by genetic and epigenetic features, as 
well as tumour microenvironment. It is recognised that expression of ER, PR and HER2 
between a primary breast cancer and its metastases is discordant in up to 40% [237] (see also 
section 5.1). Theories around establishment and maintenance of tumour heterogeneity include 
the cancer stem cell (CSC) and clonal evolution model theories. The CSC concept proposes a 
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hierarchy system whereby a minor subset of CSCs at the apex divides into multiple 
proliferating terminally differentiated cells at the base [238].  
 
The clonal evolution model proposes that cancer cells within a tumour possess varying degrees 
of genetic instability and acquire more aberrations in tumour evolution over time and in 
response to treatments. A tumour is thereby composed of cells with shared founding genetic 
events, and additionally within the tumour, multiple subpopulation cell groups with specific 
individual genetic aberrations [239].  Over time further genetic instability generates more 
alterations and diversity, many of which are lost. However, if a change promotes growth or 
survival advantage, the clone harbouring this will become predominant [239], see figure 1.8. 
Mutations which have been implicated in drug resistance may therefore become the overall 
phenotype of the tumour [86] which may contribute to acquired endocrine resistance in 






Figure  1-­8.  Subclonal  diversification  in  breast  cancer  
Intra-­tumour  genetic  heterogeneity  is  present  but  not  predominant  in  primary  tumour.  
Genetic  aberration  in  orange  and  green  cells.  
Over   time  orange   subclone  becomes  predominant   and   that   genetic   aberration  will  
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1.10.7.1  Liquid  biopsy  
Circulating tumour cells (CTCs) are assessable in plasma in patients with metastatic BC. A 
trial of 1,944 patients from 20 studies found a lower CTC count at baseline and after 3-5 weeks 
of treatment was associated with improved progression free and overall survival [240]. CTCs 
can also undergo molecular profiling to assess for biomarkers of drug resistance. Circulating 
cell-free tumour DNA (ctDNA) can also be sampled from serum and has been suggested to be 
more sensitive than CTCs in predicting treatment response [241]. Standardised measures need 
to be implemented before this novel technology is routinely available. However, in the future 
it may allow monitoring for biomarkers of resistance in the metastatic setting. Additionally in 
the adjuvant setting where there is no solid tumour to biopsy, a liquid biopsy could allow serial 
monitoring of any residual tumour burden to identify patients at risk of early relapse by 
highlighting markers of endocrine resistance [202].  
 
1.10.8   Overcoming  endocrine  resistance  
In metastatic breast cancer, combination therapies tend to be more effective than monotherapy. 
There is no doubt that dual therapies can delay the onset of acquired resistance. Tumours which 
respond to first line endocrine agents, will likely respond to second and third line agents. 
However, the progression free interval will decrease at each stage [242].  ASCO have issued 
updated guidelines for the management of ER+ metastatic breast cancer [243]. An attempt to 
summarise these and the evidence from the trials discussed above is presented in the following 
flow diagram, see figure 1.9. This is however a broad oversimplification of this complex issue. 
Realistically in patients with de novo metastatic or endocrine naïve ER+ disease, first-line  
monotherapy with an AI is most likely. A sequential approach is preferred rather than dual 
therapy at presentation, whereby one agent is utilised until there is evidence of progression, 
then a second agent is adopted until progression, then a third and so on. A further problem is 
a lack of biomarkers to predict who will benefit from each of these targeted therapies. We 
must remember the toxicities associated with novel drugs and consider their impact on quality 
of life in this cohort.  
 
   




Figure  1-­9.  Treatment  of  metastatic  ER+  breast  cancer  
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1.11   Summary  and  approaches  
The high throughput genomic technologies have revolutionised our understanding of breast 
cancer [36]. This complex disease is a spectrum with varying risks and clinical phenotypes. 
Multiple subtypes have been identified which correlate to prognosis [41]. Indeed, multiple 
methods of defining and identifying those subtypes have also been proposed. 
 
As clinicians, our aim is to stratify risk through measures of prognosis, in order to best advise 
patients on treatment. High risk disease must of course be identified early, but equally 
important is to identify the very good prognosis tumours [172], and spare these patients from 
toxic over-treatment, which would offer them little benefit. Standard clinicopathological 
disease measures are effective in estimates of prognosis, but do not always consider the innate 
biology of the tumour, which could misrepresent risk in a significant proportion of patients 
[161]. Multiple gene signatures predictive of recurrence and outcome have been proposed 
[149, 161, 169, 170, 172, 175, 177, 188], and the optimal signature is certainly still debated.  
Some promise has been demonstrated through combining variables from traditional 
clinicopathological features with molecular biomarkers [178, 189], and this is likely to prove 
to be the best option in due course.  
 
ER+ breast cancer accounts for 75% of the disease. Endocrine treatment is the mainstay of 
therapies in these patients. In premenopausal women, tamoxifen [86] plus ovarian suppression 
in high risk or young patients [113], has been established as best care. In postmenopausal 
women AIs are superior [118, 119]. Recent advances include extended duration of adjuvant 
therapy, and in the metastatic setting, sequential endocrine treatments [243], which offers a 
real option of delaying acquired resistance and disease progression.   
 
The rate of resistance to endocrine therapy approaches 50% in the adjuvant setting. The 
mechanisms by which this is achieved are complex and not fully understood. Pathways 
involved commonly include EGFR, HER2, MAPK and PI3K [201]. Genomic aberrations in 
ESR1 and PIK3CA [67], amongst other genes, have been frequently implicated in luminal 
disease. It is possible that multiple varied mechanisms of resistance are active in individual 
patients at different time points in the history of their disease. Recent large phase III 
randomised controlled trials have proven the benefit of combining standard endocrine agents 
with newer drugs, including fulvestrant with AI [110], CDK4/6 inhibitors with AI [233], and 
mTOR inhibitors with AI [218].  
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The neoadjuvant period offers a unique possibility, through sequential biopsy, to explore 
molecular changes in response to drugs, to explore prognostic and predictive biomarkers, and 
the opportunity to predict long term outcomes very early in the course of disease. Drugs which 
have been validated in the metastatic setting are now increasingly being applied in the 
neoadjuvant setting also [196]. However, we currently do not have biomarkers to predict 
which patients will benefit from particular targeted agents, and this represents a major clinical 
need.  
  
1.12   Aims  of  Thesis    
The four projects incorporated in this thesis aim to explore ER+ breast cancer and its evolution 
over time, treatment and progression. Sequential matched patient biopsies are utilised to 
reduce the variability associated with sampling and processing, and therefore increase the 
statistical power of any relevant findings. Gene expression profiling will evaluate molecular 
changes in the presence and absence of endocrine treatment and in lymph node metastases. 
Changes related to histological subtype will be explored also. The following research aims to 
establish: 
•   Comparisons of the gene expression profiles of breast cancer in the absence of 
treatment in the normal time course of the disease between diagnosis and resection. 
•   Effect of time between biopsies on any changes identified in tumour biology and any 
relationship to clinical outcome. 
•   A large negative control cohort to be used as a comparison for any future studies 
exploring biomarkers in the neoadjuvant setting.  
•   Comparison of gene expression profiles of the clinicopathologically distinct breast 
cancer subtypes; invasive lobular and invasive ductal carcinoma.   
•   Changes in gene expression profiles in response to neoadjuvant letrozole in lobular 
and ductal subtypes.  
•   Correlation of PIK3CA mutation and PTEN status in primaries and patient-matched 
recurrences and metastatic samples. 
•   Relationship of PIK3CA and PTEN status at diagnosis to long term outcome. 
•   Comparison of gene expression profiles of matched primary breast tumour and 
synchronous lymph node metastasis.  
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2   Molecular   effects   of   initial   core   biopsies   in   neoadjuvant  
window  studies  in  breast  cancer  
 
2.1   Introduction    
Endocrine therapy is effective in most invasive ER+ breast cancers however some tumours 
demonstrate innate resistance. There is a clinical need to identify these patients early, in order 
they be switched to alternative or combination therapies. The value afforded by the 
neoadjuvant window of opportunity treatment period is unquestionable. Measures of response 
to therapies and long term survival are possible after only short courses of treatment [30, 152]. 
The ACOSOG Z1031B trial recently reported poorer long-term outcomes in patients with 
higher Ki67 after 2 weeks of neoadjuvant aromatase inhibition [193]. Further trials are 
ongoing to validate the use of on-treatment biopsies as predictive and prognostic markers. 
These include ALTERNATE, where on-treatment Ki67 will determine whether to continue 
neoadjuvant endocrine therapy, or to switch to surgery or chemotherapy instead [195]; and 
NeoMONARCH, where on treatment Ki67 will be used to assess prognosis relative to 
abemaciclib, a drug relatively new to the neoadjuvant setting. Recently we identified a 4-gene 
signature which can predict response or resistance to neoadjuvant letrozole with 96% 
accuracy, based on expression of 2 genes at baseline, IL6ST (immune related) and NGFRAP1 
(apoptosis); and a further 2 genes after 2 weeks of treatment, ASPM and MCM4 (proliferation 
related) [149]. After a breast cancer diagnosis, there is an inevitable time delay before surgery 
in the order of a few weeks, to complete staging investigations and to agree on appropriate 
surgical approaches. Some argue that in ER+ disease (a result which will be available from 
the core biopsy within 24 hours usually), patients should be immediately started on endocrine 
therapy. Not only is this possibly associated with better long-term outcome [137], it also 
allows a valuable assessment of response in order that appropriate adjuvant treatment 
discussions can arise. The POETIC trial aims to assess this theory. It seems plausible that peri-
operative treatment and sequential biopsy from the same tumour is going to become 
increasingly routine in breast cancer treatment [244].  
 
There are challenges to this approach however. There is innate biological heterogeneity within 
the primary tumour [245] and with synchronous metastases [237]. Also, the ideal interval at 
which to assess response with a second biopsy is debated. Miller et al previously demonstrated 
a significantly higher proportion of genes changed at 3 months in response to neoadjuvant 
letrozole compared to 2 week biopsies in the same patient [246]. Chen et al compared the 
effect of time interval between core biopsy and surgical resection on the expression of ER, 
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PR, HER2 and Ki67 in 276 patients. They found good concordance for ER (94.2%), PR (87%) 
and HER2 (97.1%) but found Ki67 was significantly higher in the surgical specimen (29.1%) 
vs the core biopsy (26.2%), p<0.001, an effect which was significantly associated with length 
of time between the 2 biopsies (p=0.01) [247]. We note their inter-biopsy interval was very 
short, comparing groups by 1-2 days, 3-4 days or 5 days or more. It is feasible the changes 
could be even greater therefore, over longer time. It is rare for patients to have surgery so soon 
after core biopsy, therefore a longer time interval for biopsy related effect, or simply tumour 
evolution, should be explored. In a similar study Meattini et al compared IHC at core biopsy 
and surgical specimen, and found concordance of ER in 94.1%, PR in 88.1% and Ki67 in 
88.1%. Using a 15% cut off to differentiate between high and low Ki67, they applied the St 
Gallen recommendations to determine molecular subtype at both biopsies, and found 
concordance of 87.1% [248]. Although this reflects good reproducibility, they highlighted a 
subgroup of patients where again Ki67 increased at second biopsy; and in 7 patients this re-
classified them as luminal B rather than luminal A. This obviously has major implications for 
adjuvant treatment in these patients.   
 
Haded et al compared gene expression profiles by a breast cancer disease specific array, of 12 
patients at core biopsy and surgery. Pathways involving cellular metabolism and immune 
system were upregulated at second biopsy; and rho, integrin and ER pathways became down-
regulated, despite having no intervening treatment [249].  
 
Even the biopsy itself has been proposed as having an effect on the molecular evolution of a 
tumour. Morrogh et al demonstrated that 10 days exposure to neoadjuvant anastrozole 
produced significant changes in cancer related and ER regulated genes, which were not 
observed in a control group in their cohort of 31 patients [250]. They demonstrated changes 
in only 2 genes common to both treated and non-treated groups, FOSB and MLL, both involved 
in transcription, and proposed a wound healing response to the biopsy itself. This occurred 
despite ensuring the second biopsy was taken away from the site of the initial one.  
 
Although there are increasing clinical trials assessing IHC at different time points in vivo, there 
are fewer available assessing at molecular level changes in response to treatment in the same 
patient [251]. Comparing matched pre and post treatment samples from the same patient 
removes much variability, but attempts to characterise patient-matched samples following 
neoadjuvant endocrine therapy or chemotherapy previously have often been limited to 
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relatively small numbers of patients [252-256] which markedly restricts the power implication 
of any significant findings. 
 
In order that we can be certain that a drug effect observed in the neoadjuvant period is indeed 
due to that drug, a control cohort is crucial. This study incorporates one of the largest cohorts 
of patient matched core biopsy and surgical resection specimens with no intervening treatment, 
assessing gene expression profiles at both time points, in order to assess what if any, processes 
alter in the absence of treatment. We also aim to assess the effect of time interval between 
both biopsies and corresponding gene changes, exploring normal tumour evolution over time.  
 
2.2   Methods  
2.2.1   Patients    
Paired fresh frozen tissue specimens from an initial diagnostic core biopsy and a second biopsy 
(median 33 days later, range 4-106 days), were identified from 83 patients treated for a primary 
histologically confirmed invasive breast cancer at the Western General Hospital, Edinburgh, 
between 2003 and 2011. All patients gave informed consent to be included in the study, which 
was approved by the Lothian Regional Ethics Committee (2001/8/80 and 2001/8/81). From 
these a cohort of 61 patients with paired samples was selected for further analysis based on 
ER status (all patients were ER-rich with Allred scores of 6, 7 or 8 as assessed by IHC by a 
dedicated breast pathologist). The study consisted of two independent arms: 36 patients treated 
with neoadjuvant letrozole with good clinical response after 3 months (data published 
previously [149]); and 25 patients who had no intervening treatment prior to surgery (figure 
2-1). 
 
Clinical response in the letrozole treated group was assessed by periodic measurement of 
tumour volume using three-dimensional breast ultrasound by a single operator (JMD); and 
defined as reduction in tumour volume of 70% by 3 months of treatment. Patient and tumour 
characteristics were recorded from paper and electronic case note review. 
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Figure  2-­1.  No  intervening  treatment,  study  design  
  
2.2.2   Samples  
Core biopsies were taken at diagnosis in all patients using a 14-guage needle device. In the 
letrozole-treated group the second biopsy was a repeat core biopsy taken after a median 17.5-
days of treatment (range 4-106 days).  In the letrozole treated group 32 of 36 (88.9%) patients 
went on to have surgery after 3 months of neoadjuvant letrozole. In the no-intervening 
treatment arm, biopsies were taken at diagnosis and again at surgery from the resection 
specimen at a median of 23 days later (range 14-35 days). Samples were snap frozen in liquid 
nitrogen and stored at -80˚C for later use. 
 
2.2.3   RNA  processing  and  microarray  hybridisation  
Tissues were homogenised and RNA extracted using the RNeasy Mini Kit with RNAse Free 
DNAse treatment (Qiagen). RNA quantity and quality was assured using a Nanodrop 2000c 
spectrophotometer (Thermo Scientific).  RNA was reverse transcribed and amplified using the 
WT-Ovation FFPE System Version 2 (NuGEN), purified using the Qiaquick PCR purification 
Kit (NuGEN), biotinylated using the IL Encore Biotin Module (NuGEN), and purified using 
the minElute Reaction Cleanup Kit (Qiagen). At each step RNA/cDNA quantity and quality 
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was assured by repeat assessment with the Nanodrop 2000c prior to advancing to the next 
stage. Labelled cDNA was hybridized to Illumina Human HT-12v4 whole-genome expression 
bead arrays according to the standard protocol for NuGEN labelled samples. Data was 
extracted using the GenomeStudio software (Illumina).   
 
2.2.4   Data  Analysis  
Illumina data from both arms of the study were independently pre-processed and re-annotated 
to Ensembl gene identifiers, then combined with cross-platform integration approaches to 
correct for batch effects as described previously [257]. Briefly, Illumina probe profiles were 
quantile normalized using the lumi package and mapped to Ensembl gene sequences using 
reMOAT [258], BioMart [259], and a custom BLAST sequence search. The datasets were 
filtered using detection p-values, removing probes that were undetected (p>0.05). Both 
datasets were then combined and batch corrected with cross-platform normalization. Pairwise 
and grouped differential gene expression analyses was performed using rank products (RP) 
(MeV; TM4 Microarray Software Suite). Functional gene ontology analysis was performed 
using DAVID Bioinformatics Resources 6.7 and the PANTHER Classification System. Gene 
expression heatmaps were generated in MeV using Euclidean distance with complete linkage 
following gene mean-centering performed in Cluster 3.0. 
  
Clinicopathological features at diagnosis were compared using analysis of variance (ANOVA) 
for patient age and tumour size, and all other features using Fisher’s exact test; or unpaired t-
test, following construction of  contingency tables. All statistics were performed in GraphPad 
Prism version 6.00 for Windows, (GraphPad Software, La Jolla California USA).  
 
2.3   Results    
The treated and non-treated groups were well matched, with no significant differences 
observed for histology, tumour grade, nodal stage, ER or HER2 positivity. In the letrozole 
treated group there were more T4 tumours and in the non-treated group there were more T1 
tumours. This likely reflects a clinical decision to treat larger and locally advanced tumours 
with neoadjuvant letrozole in the hope of achieving breast conservation surgery at a later date. 
The groups were also well matched with regards to time between the two biopsy samples, with 
a median of 23 and 17.5 days in the no intervening treatment and letrozole treated groups 
respectively (table 2-1).  
 
   
   67  
  
 




     
   68  
2.3.1   Gene  changes  in  treated  and  non-­treated  tumours  
In the letrozole treated group differential gene expression analysis (pairwise RP, FDR 0.01) 
identified 591 genes consistently up-regulated, and 380 down-regulated in response to 
treatment, figure 2-2. Gene ontology found these genes to be functionally enriched for up-
regulation of the immune system and processes (including CXCL9, C1QB, C3, C7, CCL19, 
ACKR1), and extra-cellular matrix (ECM) remodelling (including COL1A1, COL5A2, FBLN5, 
ELN, ECM2, SPP1). Down-regulated genes were associated with proliferation, not 
unexpectedly (including AURKA, CCND1, CCNB1, CKS2, MCM2, CENPN, CHEK1, TOP2A, 
UBE2C). In the non-treated group 475 genes were consistently up-regulated and were 
functionally associated with immune processes (including ITGB2, C3, C1S, CFH, CD47, 
A2M, PLA2G7), ECM and adhesion (including FBLN2, PCDH18, COL1A1, COL5A2, 
COL6A3, SPP1, DPT), and cell cycle (including CCND2, EMP1, ITGB, RGCC, SETDB2). 
494 genes were consistently down-regulated in the non-treated group, which related to 
transcription (including FOXA1, MED27, ZBTB45, ZNF593, ATF5), and protein processing 
(including TUBA3C, TUBA1C, UBE2L6, TOMM22, OS9, USP5).   
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2.3.2   Common  changes  between  treated  and  non-­treated  tumours  
Comparison of genes changed in the treated versus non-treated (RP: FDR=0.05) patients, 
revealed overlap in only 14%, figure 2-3. In the non-treated group, 844 genes were down 
regulated and 784 up-regulated between the 2 biopsies. In the letrozole treated group, 633 
genes were down regulated and 901 up-regulated in response to treatment. Common to both 
groups were 291 genes up-regulated at second biopsy, reflecting the immune, ECM and cell 
adhesion genes described above. 157 genes were down-regulated in both groups at second 




Figure  2-­3.  Venn  diagram  of  common  differentially-­expressed  genes  in  treated  and  
non-­treated  tumours.  
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2.3.3   Changes  in  non-­treated  tumours  
Unsupervised hierarchical clustering (HCL) of the 500 most variable genes in the non-treated 
samples, at core biopsy and at theatre, revealed matched samples from the same patient 
clustered together in 18 of 25 (72%) patients, figure 2-4. In 7 patients a biopsy more resembled 




Figure  2-­4.  Unsupervised  HCL  of  500  most  variable  genes  in  non-­treated  group  
Columns  represent  patients,  patient  IDs  below  dendrogram  
Top  row  (green)  -­  core  biopsies  
Middle  row  (gold)  -­  theatre  resection  specimens  
Bottom  row  (purple)  -­  highlights  cases  where  both  biopsies  from  same  patient  cluster  
together.  
 
Comparing the 7 patients where core and theatre biopsy did not cluster together, the ‘changed’ 
group, to those ‘unchanged’, revealed these patients were younger; median age 45 years (range 
28-83) vs 65 (28-88), p=0.16; and were more likely to have a lobular rather than ductal cancer; 
3 of 7 (42.9%) vs 3 of 18 (16.7%) p=0.5. Neither of these observations reached statistical 
significance however in this small sample (unpaired t test with Welch correction).  
 
They were well matched otherwise in terms of: 
tumour size (median 21mm changed vs 20.5mm unchanged);  
inter-biopsy time interval (median 24 days changed vs 21.5 days unchanged);  
lymph node positivity; (2 of 7 (28.6%) changed vs 5 of 18 (27.8%) unchanged);  
tumour grade (5 of 7 (71.4%) grade 2 changed, 11 of 18 (61.1%) grade 2 unchanged),  
ER positivity (all patients) and HER2 status (0 in changed, 6/18 (33.3%) in unchanged).   
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2.3.4   Effect  of  time  on  non-­treated  tumours  
Non-treated patients were arranged in order of the length of time interval between baseline 




Figure  2-­5.    Interval  between  baseline  and  second  biopsy  
 
The 8 shortest inter-biopsy interval patients (yellow; mean 17 days) were compared with those 
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The overlap in changed genes was very minor between short and long inter-biopsy interval 
groups (6.2%). In the longer interval group, significantly more changed genes were identified, 




Figure  2-­6.  Venn  diagram  of  common  differentially-­expressed  genes  in  non-­treated  
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Functional analysis using PANTHER highlighted that longer inter-biopsy interval genes were 
enriched for transcription, immune response, intracellular signalling, ECM and adhesion, 




Figure   2-­7.      Numbers   of   up   (red)   and   down-­regulated   (green)   genes   in   enriched  
processes  at  short  and  long-­term  intervals  in  non-­treated  tumours.    
 
A heatmap was generated comparing treated and non-treated patients by time interval groups. 
The non-treated tumours did not show significant down-regulation of proliferation genes, 
unlike the treated samples, unsurprisingly. Increased expression of immune and ECM 
associated genes was observed in the treated tumours. Similar changes were not found in non-
treated tumours at the short time interval, however they were seen after the longer inter-biopsy 
time interval, figure 2-8. 
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Figure  2-­8.  Heatmap  of  most  differentially-­expressed  genes  in  treated  compared  with  
non-­treated  tumours  at  different  inter-­biopsy  time  intervals  
Samples  are  ordered  left  to  right  by  time  interval,  at  baseline  (BL)  and  mean  number  
of  days   to  second  sample.  Colours  represent  change   in  expression  (after   /  before)  
with  red  denoting  higher  expression  and  green  lower  expression. 
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2.4   Discussion    
Down-regulated gene processes, particularly proliferation related, were seen in letrozole 
treated tumours but not in non-treated. This is not unexpected, but adds validity to any 
neoadjuvant measure of response using proliferation as a surrogate biomarker. Previous 
studies have demonstrated increased Ki67 at second biopsy in the same tumour with no 
intervening treatment [247, 249]. In this cohort however, MKI67 was not a gene which 
featured in those consistently changed between baseline and surgery across all non-treated 
samples.  
 
In the 4-gene model predictive of response to neoadjuvant letrozole [149], the measure of 2 
genes at diagnosis (IL6ST and NGFRAP1) and 2 proliferation genes (ASPM and MCM4) after 
2 weeks of letrozole is predictive of response to treatment with 96% accuracy. However, in 
the same cohort, Ki67 assessed by IHC, which is considered a gold-standard proliferation 
marker, was not significantly different at 2 weeks in responding and non-responding groups. 
Using mRNA measures of proliferation may be a more sensitive method of tumour 
proliferation assessment than IHC, not least considering the problems in the reproducibility 
and cut off measures to assess Ki67 by IHC. We have demonstrated down-regulation of 
another common proliferation marker, AURKA, in letrozole treated tumours, which was not 
mirrored in the non-treated cohort. In a panel of proliferation associated genes, there was no 
consistent trend identified between baseline and surgery in non-treated tumours, compared 
with consistent down-regulation of these genes in letrozole-treated patients (see 
Supplementary 8-1). The non-treated cohort in this study has utility for all future neoadjuvant 
trials representing a significant negative control cohort as a comparison for newly proposed 
on-treatment biomarkers.  
 
The overlap between non-treated and treated tumours is small; with only around 14% of genes 
changing over time common to both cohorts. The non-treated cohort validates the conclusion 
that most genes changed in letrozole-treated tumours appear to be directly related to treatment, 
and are not consistently changed in non-treated tumours. This confirms the value and validity 
of an on-treatment biopsy to assess response.  
 
With longer time interval between biopsies the number of genes changing in non-treated 
tumours increases. This is similar to previous observations in letrozole treated tumours, where 
more genes changed after longer periods of treatment [145]. Genes up-regulated after longer 
non-treatment interval are related to immune processes, adhesion, and extracellular matrix. 
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Genes related to the same processes also increase in the comparative letrozole treated cohort 
at an earlier stage, and also in a previous study in response to neoadjuvant anastrozole and 
letrozole [146], albeit in greater numbers than in non-treated patients. Genes which are 
normally kept repressed by ER may become induced when ER loses its inhibition of them, 
either in E2-ER binding in non-treated tumours, or in response to endocrine therapy in treated 
tumours. This may explain the up-regulation of certain genes in both cohorts. Jeselsohn et al 
demonstrated similar upregulation of immune related genes between non-treated core and 
surgical specimen over a mean of 30 days, comparable to our findings [260]. This may reflect 
the tumour growing over time; or remodelling itself in response to an insult (biopsy related) 
in non-treated; or remodelling in response to aromatase inhibition in treated patients. We were 
unable to confirm the wound healing signature that Morrogh described in response to biopsy. 
The 2 genes highlighted in their study, FOSB and MLL did not feature in the most differentially 
expressed genes between non-treated core and surgical specimen in this cohort.  
 
In unsupervised hierarchical clustering, biopsies from the same tumour cluster together in 18 
of 25 (72%) patients. This is comparable to concordance in a similar pre-operative study where 
16 of 23 (70%) and 41 of 56 (73%) matched samples from the same patient clustered together 
[261]. In our cohort, the changed tumours tended to be in younger patients and were more 
likely to be lobular than ductal. 3 of the 7 patients, in whom samples did not cluster together, 
were also in the longer ‘inter-biopsy interval’ group. This shows that in the absence of 
treatment there are still active molecular processes, which increase over time. Comparing 
progression free and overall survival in these against non-changed tumours, did not reveal any 
adverse prognosis. The small size of this cohort however (7 patients), and relatively short 
follow up period available (median 27 months, range 1-43 months) means these observations 
lacked significance. One could theorise this may reflect tumour evolution to a more aggressive 
subtype. We have demonstrated discordance in molecular subtype, in core biopsy to surgical 
specimen with no intervening treatment, in 7 of 37 patients (18.9%)  [262]. The subtype 
changes in these patients however were not consistent, so we are unable to draw significant 
conclusions. This would be worthy of further assessment in a larger cohort however, as it could 
significantly alter adjuvant treatment decisions.  
 
A further limitation of this study is comparing 2 different methods of biopsy. In the letrozole-
treated cohort, the second biopsy was a further core biopsy, whereas in the non-treated cohort 
it was an excised surgical specimen. This would inevitably cause slight differences in the way 
the specimen was processed after acquisition; eg likely longer time to freezing, but we are 
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unable to quantify or confirm this effect. Previous work has demonstrated high concordance 
in gene expression profiles between core and surgical biopsies [263] however. Additionally, 
the numbers of samples at each time point are different in treated and non-treated; a further 
potential bias. Our cohort was reasonably well matched in clinicopathological features, 
however we did observe significantly more T4 tumours in letrozole treated, and more T1 
tumours in non-treated patients, which will of course be reflected in gene expression profiles.  
 
2.5   Conclusions  
We have demonstrated even in the absence of treatment breast cancers are evolving and 
remodelling; an effect which increases over time. There is increasing evidence of the benefit 
of short course perioperative AI treatment for a matter of weeks, whilst patients undergo 
essential staging investigations and planning for surgery. On-treatment biopsy is more 
reflective of long term outcome than baseline, therefore samples collected at baseline and 
again at surgery provide crucial prognostic and predictive biological endpoints. Further work 
is needed in a larger cohort to assess molecular changes in the surgical specimen, which may 
alter adjuvant treatments. However, this study represents one of the largest cohorts to date 
assessing gene expression profiling with no treatment, and validates the use of an on-treatment 
biopsy as true measure of drug effect, or assessment of prognosis. 
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3   Changes   in  PIK3CA  mutation  status  are  not  associated  with  
recurrence,   metastatic   disease   or   progression   in   endocrine  
treated  breast  cancer    
 
3.1   Introduction  
The phosphatidylinositol 3-kinase (PI3K) / AKT / mTOR pathway plays an important role in 
proliferation, migration and survival in breast cancer. Oncogenic activation of the pathway 
can occur through increased kinase activity due to missense mutations of the 
phosphatidylinositol (4,5)-bisphosphate 3-kinase, catalytic subunit α (PIK3CA) gene [264]. 
Mutations in PIK3CA therefore play a significant role in carcinogenesis and progression of 
breast cancer, and previous studies indicate that mutation occurs in 8-40% of breast tumours 
[67, 265-271]. PIK3CA mutations are more common in hormone receptor-positive breast 
cancers than in HER2-positive or basal-like and triple negative tumours [67, 272].  
 
PI3K pathway activation is implicated frequently in breast cancer [273], and in vitro studies 
have demonstrated pathway activation is associated with endocrine resistance and oestrogen 
independent activation of ERα [274, 275], figure 3-1. In the neoadjuvant setting, however Ellis 
et al. reported only a modest negative association between PIK3CA mutation and clinical 
response to aromatase inhibition [276]. Targeting the pathway with inhibitors of PI3K and 
mTOR combined with anti-oestrogen therapy does improve endocrine responsiveness in 
breast cancer cell lines [275]. In vivo, drugs such as everolimus, targeting the mTORC1 
component of this mTOR pathway, provide an enhanced anti-tumour response when combined 
with aromatase inhibition in the neoadjuvant [217] and metastatic setting [218]. 
 
The clinical and pathological relevance of PIK3CA mutations is poorly understood. 
Associations between PIK3CA mutation and large tumour size, higher grade, nodal 
involvement and poorer survival have been described [277], however it is far from clear 
whether there is any significant correlation with clinical outcome [278]. One study in fact 
shows PIK3CA mutation to be associated with favourable clinicopathological disease features 
and improved survival [266]. 
 
The phosphatase and tensin homolog deleted on chromosome ten (PTEN) protein is a potent 
suppressor of PI3K pathway activity. Loss of functional PTEN leads to stimulated cell growth 
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and survival [279]. Reduced PTEN protein expression has also been implicated in endocrine 
resistant breast cancer and is associated with shorter disease free survival [280].  
 
The relationship between PIK3CA mutation and PTEN is poorly understood with some 
descriptions of PIK3CA mutations and PTEN loss occurring only independently [267], and 
others where they coexist [281]. A significant proportion of breast cancers do evade anti-
oestrogen therapy through dysregulation of PIP3 either through mutated PIK3CA or loss of 




Figure  3-­1.  Schematic  diagram  of  PI3K  pathway.    
PI3K  is  activated  by  ligand  binding  to  RTK  or  mutation  of  PIK3CA  or  PIK3CB.  PI3K  
phosphorylates   PIP2   to   PIP3,   which   recruits   AKT,   which   in   turn   activates  mTOR.  
Inhibition   of   the   pathway   is  maintained   by   lipid   phosphatases   PTEN   and   INPP4B  
which  dephosphorylate  PIP3  and  PIP2  respectively.    
RTK  –  Receptor  Tyrosine  Kinase,  PI3K  –  phosphatidylinositol  3-­kinase,  
PIP2  –  phosphatidylinositol  4,5-­bisphosphate,    
PIP3  -­  phosphatidylinositol  3,4,5-­trisphosphate,  
mTOR  –  mammalian  target  of  rapamycin,    
INPP4B  –  inositol  polyphosphate-­4-­phosphatase,  
PTEN  –  phosphate  and  tensin  homolog  
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Endocrine resistance is problematic in the management of ER+ breast cancers.  Loss of ERα 
[284] or mutations in ESR1 [221, 285] in metastatic tumours, leading to ligand independent 
activation of ER, are possible reasons for endocrine resistance. Discordance in protein receptor 
status (ER, PgR and HER2) between primary and metastatic breast tumours has been widely 
reported [286], and alternative receptor status in recurrent disease could lead to a different 
treatment plan for as many as one in six patients [287]. Recent recommendations state 
metastases should be biopsied in order to best personalise treatment in these patients, though 
this is not yet part of routine clinical practice [288].  
 
As PIK3CA mutation and PTEN loss are being investigated as potential predictors of response 
to novel PI3K inhibitors, and as possible mechanisms of endocrine resistance, it is prudent to 
know whether PIK3CA/PTEN status in primary breast tumours is concordant with that in 
metastatic lesions. Gonzalez-Angulo et al. found similar rates overall of PIK3CA mutation in 
primary tumours and distant metastases (40.4% and 42% respectively) and PTEN loss (30.4% 
and 25%) in their study of 50 matched patient samples of primary and asynchronous distant 
breast cancer recurrences. However within individual patients there was discordance between 
primary and recurrent PIK3CA mutation status in 18%, and PTEN status in 26% [289].  
Dupont Jensen et al. found PIK3CA mutations in 45% of primary tumours and only 34% of 
synchronous metastatic axillary nodes. In later metastases they found a higher incidence of 
PIK3CA mutations, postulating mutations may be acquired in disease progression. Indeed they 
even found heterogeneity within areas of the same primary tumour in 4 of 10 patients using 
laser capture microdissection [290]. PTEN was also significantly higher in metastases than in 
the primary tumour.  
 
The aim of this study was to assess PIK3CA mutations and PTEN status in a unique cohort of 
patients with ER+ breast cancer who have developed resistance to endocrine therapy. This 
study utilises an exclusive cohort of matched paired samples from patients with ER+ breast 
cancer at both diagnosis and on progression, at the time of recurrence or development of a new 
breast cancer following endocrine treatment, in order to assess whether mutation status 
changes over time or is constant. This may provide further verification for the role of novel 
PI3K inhibitors as adjunctive treatment of endocrine resistant disease.   
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3.2   Methods  
3.2.1   Patient  samples  and  endocrine  treatment  
Paired formalin fixed paraffin embedded (FFPE) tissue samples were located for a series of 
120 patients treated at the Western General Hospital, Edinburgh between 1990 and 2011 for a 
primary and recurrent breast cancer. All patients had hormone receptor positive disease at first 
diagnosis and received endocrine therapy; either tamoxifen, letrozole, anastrozole, exemestane 
or a combination of these as adjuvant or primary endocrine therapy, then developed disease 
progression, recurrence or a further primary breast cancer. Samples were taken at diagnosis 
and from five classes of secondary event;  
local recurrences (in breast tumour recurrence, or chest wall recurrence);  
metastatic recurrences (axillary or supraclavicular fossae nodal metastases);  
local progression (patients treated with primary endocrine therapy who initially responded 
well and then progressed); and  
from second breast cancers (ipsilateral second primary breast cancers, or contralateral new 
primaries).  
 
Where the secondary event was a recurrent tumour in the treated breast, pathology and 
mammography records were assessed to determine whether these second tumours represented 
in breast local recurrences or true second primary breast cancers.  Clinicopathological disease 
features, tumour characteristics, treatment regimens and survival data was traced from 
electronic and paper case note record review. Pathology reports issued at the time of treatment 
were prepared by dedicated breast pathologists. Data was incomplete across every field in 17 
of the original 120 samples, mostly due to historic case records being unavailable. All patients 
gave informed consent to be included in the study which had been approved by the local ethics 
committee (LREC; 2001/8/80 and 2001/8/81). 
  
3.2.2   PIK3CA  mutation  status  
Five 5-µm sections were cut from each FFPE tumour block and DNA extracted using the 
QIAamp FFPE kit (Qiagen) after deparaffinisation with Envirene, as described previously 
[291]. 150ng of DNA from each sample was profiled using the Roche PIK3CA Mutation Test, 
a multiplex PCR assay designed to detect 8 mutations in exons 7, 9 and 20 in the PIK3CA 
gene [292]. The analytical sensitivity of the assay, defined as ≥95% mutation detection rate, 
has previously been shown to be ~5% mutant allele in breast cancer FFPE tumour sections 
representing the 3 most prevalent PIK3CA mutations (H1047R, E545K, and E542K). 
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3.2.3   Immunohistochemistry  
Oestrogen receptor status was determined as part of routine clinical evaluation using the Allred 
classification system. HER2 status assessed by IHC and FISH was determined routinely on all 
patients diagnosed after 2004 when this entered routine clinical practice. PTEN IHC was 
conducted at a central laboratory (Histogenix, Belgium) on FFPE tumour samples using the 
Discovery XT automated staining platform (Ventana, Tucson, AZ).  Antigen retrieval was 
performed with Cell Conditioning I reagent (CC1, Ventana). The primary antibody was from 
Cell Signaling Technologies (clone 138G6).  Reactions were developed using the UltraMap 
DAB detection system (Ventana), and counterstained with Hematoxylin II (Ventana).  PTEN 
was scored in a semi-quantitative fashion using a H-score  method to account for heterogeneity 
of expression, as described previously [291], and staining of normal stromal components of 
each sample was used as an internal control for sample integrity. In subsequent statistical 
analyses, a H-score of 100 or less was used as the cut-off to designate loss of PTEN. 
 
3.2.4   Survival  Analysis  
Progression free survival was calculated from the date of biopsy confirming recurrent disease, 
compared to the date of the original sample. Overall survival was calculated from date of death 
in the patient medical records compared with date of primary sample. Survival data was 
available in 88 patients with known PIK3CA status at primary event and 44 patients with both 
PIK3CA and PTEN status known at primary event. Progression free and overall survival was 
assessed in mutant and non-mutant groups using Kaplan-Meier survival analysis with log rank 
(Mantel Cox) comparison of curves. Features of patients and tumours at diagnosis by mutation 
group were compared using analysis of variance (ANOVA) for age and tumour size, and for 
all other features using Fisher’s exact test following construction of contingency tables. 
Comparison of recurrence type by mutation status was performed with Fisher’s exact test in 
contingency tables. All statistics were performed in GraphPad Prism version 6.00 for 
Windows, (GraphPad Software, La Jolla California USA). 
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3.3   Results    
PIK3CA mutation status and/or PTEN immunohistochemistry was obtained for 96 of the 
original 120 patient cohort. Of these 89 had PIK3CA mutation status available from both the 
primary and secondary events; and 42 had PTEN immunohistochemistry from both primary 
and secondary events. One patient had only DCIS in the biopsy at diagnosis and a contralateral 
invasive cancer as secondary event, and was excluded from further analysis. All other patients 
had histologically confirmed invasive breast cancer which was hormone receptor positive at 
diagnosis. Patient clinicopathological disease features and treatment regimens were recorded 
from case note review for the available 96 cohort and tabulated by mutation status, table 3-1. 
The mean age of the cohort was 66.3 years at diagnosis; 78% of tumours were ductal histology; 
79% nuclear grade 2-3 and 85% had high ER expression (Allred scores 6-8). Twenty-eight 
patients (29.2%) received endocrine therapy as primary or neoadjuvant endocrine treatment, 
whilst all others received it as adjuvant therapy following surgery and tumour resection.  
 
Twenty-seven of the adjuvant therapy group (39.7%) received additional systemic 
chemotherapy with an anthracycline based +/- taxane regime. Fifty-one (75%) received 
regional radiotherapy following surgery for their primary cancer. The interval between 
primary and secondary event ranged from 69 days to 18.5 years with a median of 2.4 years. 
Within mutation groups there were no significant differences in tumour size, grade, histology, 
lymphovascular invasion, nodal status or ER Allred score. There was no correlation between 
ER Allred score and PTEN expression or PIK3CA mutation. PTEN loss however was found 
in a significantly older subgroup of women compared with those with PIK3CA mutations 
(mean 77.3 vs 62.1 years, one-way ANOVA with Tukey multiple comparisons, p=0.05) 
although in this study our PTEN loss cohort is of limited size (7 women).   
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Table  3-­1.  Patient  and  tumour  characteristics  at  primary  event    
DCIS  –  ductal  carcinoma  in  situ,  AI  –  aromatase  inhibitor  
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3.3.1   PIK3CA  mutation  status  
PIK3CA mutation status was determined for both primary and matched interval samples for 
89 patients. Of these, 38 (42.7%) had at least one PIK3CA mutation at diagnosis, and 37 
(41.2%) had a mutation present in tissue taken at the time of recurrence. The most common 
mutations in order were H1047R (35 samples), E545K (17 samples), H1047L (11 samples), 
E542K (5 samples), E545A (2 samples), C420R (2 samples). A further 3 cancers had a 
combination of mutations. The incidence of each mutation was similar at both primary and 




Figure  3-­2.  PIK3CA  mutation  status  in  primary  and  secondary  breast  tumours  treated  
with  endocrine  therapy  
A:   PIK3CA   protein   and   functional   domains   demonstrating   position   of   mutations  
assayed  in  this  study.    
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Across the cohort only 14 patients (15.7%) had a change in their PIK3CA mutation status 
between primary and secondary event. The type of recurrence in those patients with altered 
PIK3CA status is demonstrated in Table 3-2. A change in PIK3CA status was demonstrated in 
more patients who developed a second primary breast cancer in either the treated (3/5, 60%; 
Fisher’s exact test p=0.03) or contralateral breast (5/6, 83.3%; Fisher’s exact test p=0.0003); 




Table  3-­2.  PIK3CA  mutation  gain  or  loss  between  primary  and  secondary  event  
  
3.3.2   PTEN  activity  
PTEN status was available at both primary and secondary event in 42 matched patient samples. 
PTEN loss, defined as H score 100 or less, was similar at both time-points, seen in 7 (16.7%) 
patients at primary event and 8 (19%) at secondary event. Across individual patients there was 
little variation in PTEN status, with only 4 patients who had PTEN wild type tumours at 
primary event acquiring loss of PTEN by secondary event, using the H score 100 cut-off. 
When looking at absolute values however variance between primary and secondary tumour in 
the majority of patients who changed from WT to PTEN loss and vice versa was small 
(difference in H score <100). Two patients were exceptions to this with large changes in PTEN 
expression (100 at primary event to 290 at secondary event; 300 at primary event to null at 
secondary event), figure 3-3.  
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Figure  3-­3.  PTEN  expression  by  H  score  at  primary  and  secondary  event  
Changes   in   PTEN   expression   between   primary   and   secondary   breast   cancer  
following   endocrine   treatment.   Line   plot   shows   matched   primary   and   secondary  
breast  tumours  from  patients  treated  with  endocrine  therapy.  Immunohistochemistry  
was  quantified  by  H-­score  
  
Assessing PTEN as a continuous variable demonstrated a slightly higher PTEN value in 
metastatic samples (mean H score 227.3, SD117.2); compared to primary samples (mean 185, 
SD 95, unpaired t test with Welch’s correction p=0.07). The number of PTEN null cases 
increased at secondary event compared to primary (3 of 42 at recurrence, (7.1%); 0 at primary 
event). There were also more cases of over expression (>200) of PTEN at secondary event (27 
of 42, 64.3%) compared to primary event (17 of 42, 40.5%). Many of the tumours with PTEN 
loss were located in women whose disease progressed whilst on primary (neoadjuvant) 
endocrine therapy (5 of 15 at primary event, 6 of 15 at secondary event), table 3-3.  
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Table  3-­3.  Patients  with  PTEN  loss  compared  to  type  of  secondary  event  
  
3.3.3   PIK3CA  and  PTEN  status  and  progression  free  and  overall  survival  
The mean time to progression across the whole cohort was 3.8 years (range 69 days – 18.5 
years, median 2.4 years). Patients with PTEN loss at diagnosis had a significantly shorter time 
to progression than those with retained PTEN (mean 1.3 years vs 4.9 years; log-rank (Mantel 
Cox) test p=0.006), figure 3-4A. Patients with PIK3CA mutations at diagnosis had a mean 
time to progression of 3.8 years, which was not significantly different from PIK3CA wild type 
patients (mean 4.2 years), figure 3-4B.  Further analysis of patients who had results for both 
PIK3CA and PTEN status available at primary sampling (n=44) upheld this significantly 
shorter time to progression seen with PTEN loss, which is independent of PIK3CA status, 
figure 3-4C; although our sample size is relatively small with only 7 of 44 patients (15.9%) 
demonstrating loss of PTEN at primary event. There were no significant differences in overall 
survival between mutant and wild type groups based on mutation status at primary event in 
either PIK3CA or PTEN. There was no significant difference in progression free or overall 
survival in PIK3CA mutant tumours by location of PIK3CA mutation at diagnosis in this 
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Figure  3-­4.  Progression  free  survival  by  PIK3CA  and  PTEN  status  at  primary  event.    
A:  PTEN  status  in  primary  tumour  and  time  to  recurrence  (n=44).  
B:  PIK3CA  status  in  primary  tumour  and  time  to  recurrence  (n=88).    
C:   Assessment   of   both   PTEN   and   PIK3CA   status   in   primary   tumour   and   time   to  
recurrence  (n=44);;  demonstrating  PTEN  loss  is  associated  with  significantly  shorter  
time  to  recurrence  independent  of  PIK3CA  status.    
Loss  of  PTEN,  but  not  PIK3CA  is  associated  with  poor  prognosis.  WT  –  wild  type.  
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3.4   Discussion  
This study demonstrates that PIK3CA mutation and PTEN status are usually maintained in 
asynchronous breast cancer metastases. As the samples profiled in this study were taken from 
breast tumours that developed endocrine resistance during or after endocrine treatment, this 
does not support the hypothesis that acquirement of PIK3CA mutation is associated with 
development of endocrine resistance. In a recent study, Barbareschi et al found that PIK3CA 
mutations and / or PTEN loss in HER2+ breast carcinomas treated with trastuzumab are not 
related to resistance to anti-HER2 therapy [293].  Approximately 80% of PIK3CA mutations 
have been localised to three hot spots resulting in single amino acid substitutions; E545K and 
E542K in the helical domain (exon 9), and H1047R in the kinase domain (exon 20). Based 
upon a meta-analysis of PIK3CA mutations in several cancer types, Barbi et al. suggested that 
the ratio between mutation prevalence in exons 9 and 20 might be considered a signature of 
cancer type, although it was less clear whether an exon bias exists in breast cancer as many 
studies are apparently contradictory [294]. A difference between exon preference between 
lobular and ductal histotypes has previously been suggested [295], with mutations in exon 20 
more common in ductal carcinomas and mutations in exon 9 more common in lobular breast 
cancers. Most previous studies have focused on just these mutational hotspots regions of 
PIK3CA in exons 9 and 20 [295, 296], however additional mutations have also been identified 
in exons 1, 4, 7, 13 and 18 [267]. These are rarely identified and less is known about their 
functional relevance. In this study 61.3% (46 of 75) mutations were observed in exon 20 
(kinase domain) and 32% (24 of 75) in exon 9 (helical domain).   
 
Our findings are consistent with a recent study which found that PIK3CA mutation status is of 
limited prognostic relevance in ER+ breast cancer patients treated with hormone therapy [278]. 
Our findings are also consistent with a study showing that PI3K and AKT1 mutations occur 
early in breast carcinoma [265] and that these are constant over time in the majority of patients. 
When looking at type of metastases we have shown that PIK3CA mutation status is more likely 
to change in development of a second primary breast cancer in the treated or contralateral 
breast rather than in local or metastatic nodal recurrence. Tumours with PIK3CA mutation 
were most often associated with persistent ER expression. In vitro studies have shown that 
oestrogen deprivation increases the apoptotic effects of PI3K and dual PI3K/mTOR inhibitors 
in ER+ disease, providing a rationale for PI3K/aromatase inhibitor combinations as a first-line 
therapy [297]. Targeting PIK3CA mutant tumours with a PI3K pathway inhibitor and 
fulvestrant is therefore a feasible strategy for aromatase-inhibitor-resistant ER+ relapsed 
breast cancer [297].  
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Although our sample size was relatively small, we have described a significant association 
between loss of PTEN and shorter time to progression in ER+ breast cancers, similar to that 
observed by Shoman et al. [280]. It is also interesting that tumours with PTEN loss were more 
often seen in older women. We have demonstrated that PIK3CA mutation can occur in 
combination with PTEN loss in a small number of patients and that poorer progression free 
survival seen with PTEN loss tumours is maintained irrespective of PIK3CA status.  
 
To measure the accurate functional activity of the PI3K pathway it may be necessary to look 
beyond PIK3CA mutations and PTEN status to aberrations of other genes including PIK3CB, 
AKT1/2, PDK1 and INPP4B. A previously reported PI3K/mTOR-pathway gene signature 
(PIK3CA-GS) [298] has been used to estimate the level of PI3K pathway activation in two 
clinical trials of newly diagnosed ER+ breast cancer patients (n=81); one of which was 
randomized between letrozole and placebo vs letrozole and everolimus [299]. In the 
randomised dataset, the PIK3CA-GS could identify those patients with the largest relative 
decreases in Ki67 to the combination of letrozole and everolimus compared with letrozole 
alone. PIK3CA genotype was not significantly associated with any endpoint in either dataset 
in this study [299].  
  
3.5   Conclusion  
The acquisition of mutations in PIK3CA is not responsible for the development of endocrine 
resistance. PIK3CA mutation status does not change in the majority of patients who develop 
recurrent or progressive breast cancer. Therefore, if PIK3CA mutation status is predictive of 
response to PI3K inhibitors, then mutation status at diagnosis can be used to determine whether 
a PI3K inhibitor might be suitable for treatment for subsequent metastatic disease. Patients 
who develop new breast cancers frequently develop cancers with a different PIK3CA mutation 
status indicating that PIK3CA mutation status of different cancers can vary in individual 
patients. PTEN loss can exist in combination with PIK3CA mutation and is associated with 
significantly shorter time to recurrence in ER-positive breast cancers. These are the most 
comprehensive data currently available correlating PIK3CA status, location of disease 
recurrence and endocrine resistance.  
  
     
   93  
4   Molecular   changes   in   lobular  breast   cancers   in   response   to  
endocrine  therapy  
 
4.1   Introduction  
Invasive lobular carcinoma (ILC) accounts for approximately 10-15% of newly diagnosed 
breast cancers [300-302], affecting roughly 30,000 women annually in the United States [302] 
and roughly 7,000 annually in the United Kingdom [303]. ILC is classically characterised by 
small, regular uniform neoplastic cells that invade the stroma in a single-file pattern with cells 
encircling normal breast tissue [300, 301, 304, 305]. Inactivation of e-cadherin (CDH1) by a 
variety of molecular mechanisms is considered a characteristic of ILC [13, 306]. The pattern 
of infiltration explains why ILC is often large and why the extent of the tumour may be 
substantially underestimated by both physical examination and mammography [307]. When 
compared with the more common invasive breast cancers of no special type, also known as 
invasive ductal carcinomas (IDC), ILC is more likely to be oestrogen receptor-positive and of 
lower nuclear grade [308, 309]. Because ILC is often large at diagnosis, there are numerous 
reports of the response of these cancers to primary (neoadjuvant) chemotherapy [308, 309]. 
Patients with ILC are significantly less likely to have a pathological complete response than 
IDC patients. However a recent study concluded that ILC represents a heterogeneous group of 
tumours and the difference in response to neoadjuvant chemotherapy is largely explained by 
differences in molecular characteristics, particularly ER, PR and HER2, and independent of 
lobular histology [310]. The lack of understanding of lobular breast cancer is compounded by 
the paucity of research models (reviewed in [302]).  A recent study suggested that E2 and anti-
oestrogens differentially regulate ERα-mediated gene expression in ILC versus IDC cell lines 
[311].  
 
Previous microarray studies of ILC tumour samples have focused on transcriptional 
differences between lobular and ductal histology before treatment [312-316]. To our 
knowledge, there have been no previous studies on the molecular response to endocrine 
therapy in ILC patient samples. We recently described the clinical response to neoadjuvant 
letrozole in a series of 61 ILC patients [317] and we and others have characterised the 
molecular response to endocrine therapy in breast cancer in previous studies [146, 147, 318], 
but have not considered the effect of histological subtype. Comparing pre- and post-treatment 
biopsies from the same patients, utilising the ‘window of opportunity’ afforded with 
neoadjuvant therapy [319] is a powerful approach which can improve statistical power due to 
reducing patient-patient variation. However these studies are challenging to perform and are 
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dependent on analysing sufficient numbers of suitably appropriate samples. In this study we 
have performed the first gene expression profiling study of ILCs treated with neoadjuvant 
letrozole and compare the molecular response to that of IDCs.  
 
4.2   Methods  
4.2.1   Patients  
Samples were selected from a consecutive series of 89 postmenopausal women presenting to 
the Edinburgh Breast Unit (Western General Hospital) between 2003 and 2011. Each had a 
large primary histologically confirmed invasive breast cancer, immunohistochemically 
determined to be oestrogen receptor positive. All patients gave informed consent to be 
included in the study which was approved by the local Lothian Regional Ethics Committee 
(LREC; 2001/8/80 and 2001/8/81). Patients were treated within a neoadjuvant protocol in 
which letrozole (Femara, 2.5mg; Novartis Pharma AG, Basel, Switzerland) was given daily.  
 
4.2.2   Tumour  Samples  
Tumour biopsies were taken with a 14-guage needle before and approximately 2 weeks (range 
10-19 days) and 3 months (range 86-142 days) following commencement of continuous 
letrozole treatment as described previously, figure 4-1. Samples were snap-frozen in liquid 
nitrogen and frozen sections taken, stained with haematoxylin and eosin (H&E) and the 
cellularity and percentage presence of cancerous tissue within each specimen was assessed by 




Figure  4-­1.  Neoadjuvant  letrozole  in  IDC  and  ILC,  study  design  
   95  
4.2.3   Response  Assessment  
Clinical response was determined using dynamic changes in tumour volumes assessed by 
repeated measurements taken over the 3 month treatment period. Primary assessment was 
based on ultrasound measurements performed by a single clinician (JMD) and these were 
verified by mammographic measurements, figure 4-2. Clinical response was defined as a 




Figure  4-­2.  Dynamic  clinical  response  to  letrozole.        
Red  –  ILC  patients,  blue  –  IDC  
 
4.2.4   RNA  Processing  and  Microarray  Hybridisation  
Biopsies were homogenised and RNA was extracted using the RNeasy Mini Kit with RNAse-
free DNAse treatment (Qiagen). RNA quantity and quality was verified on a Bioanalyser 2100 
with RNA 6000 Nano Kit (Agilent) and Nanodrop 2000c (Thermo Scientific). RNA was 
reverse transcribed and amplified using the WT-Ovation FFPE System Version 2 (NuGEN), 
purified using the Qiaquick PCR Purification Kit (Qiagen), biotinylated using the IL Encore 
Biotin Module (NuGEN), purified using minElute Reaction Cleanup Kit (Qiagen) and 
quantified once again using the Nanodrop 2000c (Thermo Scientific). Labelled cDNA was 
hybridised to Human HT-12v4 whole-genome expression beadarrays (Illumina) according to 
the standard protocol for NuGEN amplified samples. The Illumina data have been submitted 
to the NCBI Gene Expression Omnibus (GEO) and are available under GSE55374. 
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Approximately half of the ILC and IDC samples were processed on Affymetrix GeneChips 
within a previous study [147], these are publicly available from NCBI GEO under GSE20181.  
 
4.3   Data  Analysis  
The llumina and Affymetrix data were independently pre-processed and re-annotated to 
Ensembl gene identifiers, then combined and batch corrected as described previously [257]. 
Briefly, Illumina probe profiles were quantile normalised using the lumi package [258] and 
mapped to Ensembl gene sequences using reMOAT [259], BioMart and a custom BLAST 
sequence search. A custom Chip Definition File (CDF) [320] was used to map the Affymetrix 
data to Ensembl. The Affymetrix portion of data was normalised by robust multi-array average 
method implemented by the affy package. The datasets were filtered using detection P-values, 
removing probes that were undetected (p>0.05 in the total minus 3 samples). Both datasets 
were then combined and batch corrected with cross-platform normalisation (XPN; 
ArrayMining) [257, 321, 322]. A subset of samples was profiled on both platforms and 
demonstrated successful minimisation of batch effects [257]. Pretreatment tumours were 
assigned to molecular subtypes using the Sorlie and colleagues centroids [43] as described 
previously [259]. Paired and unpaired Rank Products analysis [323] was used to identify 
differentially expressed genes and Gene Set Enrichment analysis (GSEA) was performed with 
the phenoTest package. Functional gene ontology analysis was performed using DAVID 
Bioinformatics Resource 6.7 and the PANTHER classification system. Differences in 
clinicopathological features and platforms between the ILC and IDC samples were assessed 
by chi squared test.  
 
4.4   Results  
From a cohort of sixty-one patients with ILC treated with neoadjuvant letrozole [317], surgery 
was possible for 24 cancers after 3 months. Sufficient quality and quantity of RNA for gene 
expression profiling was available for matched pre-treatment and 3 month samples for 14 of 
these patients with ILC who had a clinical response to letrozole. Pre- and 3-month letrozole-
treated transcriptome data was also selected for a further 14 patients with IDC that responded 
to letrozole. Patients were matched for clinicopathological features, table 4-1, and response, 
figure 4-2, and the histopathological status was confirmed by a pathologist, representative 
images figure 4-3. Consistent with previous studies [312-315], unsupervised hierarchical 
clustering of the pre-treatment samples using the 500 most variable genes across samples at 
pre-treatment was able to distinguish between IDC and ILC with 86% accuracy, figure 4-4. 
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Table  4-­1.  Clinicopathological  features  of  ILC  and  IDC  patients  
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Figure  4-­3.  Representative  images  of  response  to  neoadjuvant  letrozole  in  ILC  and  
IDC.    
ILC  is  characterised  by  cancer  cells  invading  the  stroma  in  single  file  patterns.  Blue  
arrow,   cytoplasmic   eosinophilic   inclusions;;   red   arrow,   vacuolated   cytoplasm;;   and  
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Figure   4-­4.   Unsupervised   HCL   of   500   most   variable   genes   in   ILC   and   IDC   pre-­
treatment.    
On  dendrogram:  Red  –  ILC,  blue  -­  IDC.    
Heatmap:  Red  -­  higher  expression,  green  -­  lower  expression  
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4.4.1   Molecular  differences  between  ILC  and  IDC  are  maintained  on  treatment  
Supervised analysis (Rank Products, percent false present PFP=0.05) identified 206 genes 
differentially expressed between the histological subtypes prior to treatment. The 70 genes 
that had lower levels of expression in ILC than IDC tumours, were functionally enriched for 
immune and extra-cellular matrix (ECM) remodelling genes, including several highlighted in 
previous studies including e-cadherin (CDH1), osteopontin (SPP1) and epithelial cell 
adhesion molecule (EPCAM). Similarly, many of the 136 genes with significantly higher 
expression in ILC than IDC have previously been shown to distinguish between these 
histologic subtypes [313-316], and include CAV1, AOC3, FAB4, VWF, TF, CD36, EGR1, 
IER2 and PLIN1, figures 4-5 and 4-6. Over half of the genes found to be significantly 
differentially expressed between the histological subtypes before treatment (including all of 
those highlighted) were still significantly differentially expressed after 3 months of treatment, 
figure 4-6. Therefore, differences in gene expression between ductal and lobular carcinomas 
are maintained during treatment, as illustrated using multidimensional scaling of the 206 pre-
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Figure  4-­5.  Differences  between  ILC  and  IDC  are  maintained  on  treatment.  
Left  -­  Venn  diagram  shows  overlap  of  genes  lower  (top)  and  higher  (bottom)  in  ILC  
than  IDC  at  pre-­treatment  and  3  months  (3m)      
Right  -­  Heat  map  (RP  PFP  0.05)  showing  changes  in  same  genes  between  ILC  and  










Figure   4-­6.   Boxplots   for   genes   previously   identified   as   differentially   expressed  
between  ILC  and  IDC  









Figure   4-­7.   Multidimensional   scaling   plot   of   206   genes   differentially   expressed  
between  ILC  and  IDC  at  baseline  are  maintained  on  treatment  over  time  
Red  –  ILC,  Blue  –  IDC  
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4.4.2   Highly  similar  molecular  response  to  letrozole  in  ILC  and  IDC  
Gene expression profiles of surgical samples after 3 months of letrozole treatment were 
compared with their representative patient-matched pre-treatment biopsy samples using a 
pairwise Rank Products analysis (PFP=0.05) for ILC and IDC patients. Over half of the 
changed genes in response to letrozole were significantly up or down regulated in both 
histological subtypes. Figure 4-8 demonstrates clearly that the molecular effects of treatment 
are virtually uniform (even after just 2 weeks), in the two subtypes, with the same genes up- 






   105  
  
 
Figure  4-­8.  Genes  differentially  expressed  between  ILC  and  IDC  at  pre  and  3  month  
samples  
A:  Venn  diagrams  show  overlapping  genes  consistently  up-­  and  down-­regulated   in  
response  to  letrozole  in  ILC  and  IDC,  comparing  3  month  and  pre-­treatment  samples  
by  pairwise  Rank  Products  analysis  (FDR  0.05).    
B:  Heatmap  shows  genes  consistent  and  specific  to  ILC  or  IDC,  the  colours  represent  
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This result is somewhat at odds with a recent study that found that E2 and anti-oestrogens 
differentially regulate ERα-mediated gene expression in ILC (MDA-MB-134VI and 
SUM44PE) and IDC (MCF7, T47D and BT474) cell lines [311]. However, we found that the 
‘ILC-specific’ and ‘IDC-specific’ genes identified in this study were not significantly changed 
in the clinical samples after neoadjuvant letrozole, figure 4-9. Gene set enrichment analysis 
(GSEA) was performed to compare the response between histological subtypes and confirmed 
consistency of the gene lists before and after treatment (p<0.0001), figure 4-10. Furthermore, 
none of the differentially regulated genes highlighted in ILC cell lines and represented in our 
data (CA12, NEDD9, CXCL12, PDE4B and NR3C2) were significantly differently regulated 
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Figure  4-­9.  Heat  map  of  'ILC  and  IDC  specific'  genes  in  both  groups  at  2  weeks  and  
3  months.  
Gene  lists  previously  identified  in  cell  line  study  [311].  Heat  map  shows  representation  
of  these  genes  in  our  clinical  letrozole  treated  samples.  Each  specific  gene  list  shows  
very  little  change  over  time  in  response  to  letrozole  in  both  histological  subtypes.    
Dendrogram  –  Red  ILC,  Blue  IDC.    
Heatmap  –  red  –  higher  expression,  green  –  lower  expression  
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Figure  4-­10.  Gene  Set  Enrichment  Analysis  of  ILC-­specific,  common  and  IDC-­specific  
gene  lists.  
Specific  gene  lists  identified  in  previous  cell  line  study  [311].  GSEA  shows  how  these  
gene  lists  are  represented  across  all  samples  in  our  letrozole-­treated  patient  cohort  
at  2  weeks  and  3  months  of  treatment.  GSEA  shows  consistency  in  gene  lists  between  
all  ILC  and  IDC  samples  at  both  2  weeks  and  3  months  showing  there  is  no  significant  
change  in  these  genes  in  response  to  letrozole.    
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Figure  4-­11.  Differentially  regulated  genes  from  ILC  cell  line  study  
Despite  being  highlighted  as  differentially  regulated  in  ILC  and  IDC  cell  lines,  these  
genes   show  consistent   expression   in   the   patient   treated   cohort  with   no   significant  
change  in  response  to  letrozole.    
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Whilst there are distinct genes which differentiate ILC from IDC tumours, these remain 
constant in response to letrozole and can still differentiate between the 2 histopathological 
subtypes at different points in treatment. The genes that do change in response to letrozole 
however are almost uniformly changed across all specimens, independent of histopathological 
subtype.  
 
Perhaps not surprisingly, and consistent with previous studies [147, 318], the genes that were 
most significantly changed in response to letrozole in both ILC and IDC tumours were 
characterised by down-regulation of proliferation and up-regulation of extracellular matrix 




Figure  4-­12.  Functional  association  of  genes  changed  with  treatment  by  3  months  
Each  gene  was  assigned  to  only  one  group  which  was  the  most  significantly  enriched  
functional  process  or  pathway  as  determined  by  DAVID  Bioinformatics  resource  6.7  
and  the  PANTHER  classification  system.     
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4.5   Discussion  
Our study shows for the first time that the molecular response to endocrine therapy in ILCs is 
highly similar to the response in IDCs. This is somewhat surprising given that we and others 
[313-316], have demonstrated clear molecular differences between tumours prior to treatment. 
The present study demonstrates that these differences are maintained during treatment. 
Stratified medicine seeks to identify molecular differences between patients cancers that will 
allow targeted treatment with specific agents, yet although these histological subtypes of breast 
cancer are molecularly distinct, both respond in a highly uniform way to endocrine therapy. 
The consistent molecular changes in expression observed in response to letrozole in both ILC 
and IDC contrast with a recent study that found that E2 and anti-estrogens differentially 
regulate ERα-mediated gene expression in ILC and IDC cell lines [311]. Whilst there are 
obvious possible explanations, including different responses to alternative endocrine agents 
and the degree to which a small number of cell lines represent the molecular heterogeneity of 
primary breast tumours, we believe that our study demonstrates the value and need for 
performing molecular studies in patient samples undergoing treatment, rather than in cell lines. 
One of the possible reasons behind the similar molecular response to treatment observed in 
ILC and IDC in this study is that we selected only responsive tumours from both histological 
subtypes.   
 
Previous work from our group has suggested that there is greater molecular diversity in the 
gene changes seen between individual non-responding tumours when treated with aromatase 
inhibitors, whereas in responders the changes are relatively homogeneous [147]. Thus, the 
resistance mechanisms still may be different between the ILC and IDC despite the similarities 
found in the present study.  This may warrant a further extension of this study focused on the 
different resistance pathways in non-responding tumours of the different pathological types.  
However, we have recorded that some non-responding tumours have molecular changes 
similar to responders; notably reductions in oestrogen-regulated and proliferation genes, 
without a clear clinical response [148].  
 
Whilst the number of patients in this study is relatively modest, the ILC and IDC patient groups 
consist of cancers with a consistently high Allred ER score of 7 or 8, all luminal A subtype, 
grade 2 or 3 and had similar responses to letrozole. High numbers of genes were significantly 
differentially expressed between the two subtypes, demonstrating clear distinctions between 
these cancers which was maintained at all time points. The study also supports the potential 
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value of cross-platform integration of datasets to generate larger datasets with increased power 
given that clinical samples are relatively scarce.      
 
In conclusion, we have performed the first study of molecular changes in ILC in response to  
endocrine therapy. The genes which change on letrozole treatment are highly similar in ILC 
and IDC although clear molecular differences between the histological subtypes are evident 
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5   Molecular   characterisation,   subtype   concordance   and  
prognostic   group   assignment   between   patient-­matched  
primary  breast  tumours  and  axillary  lymph  node  metastases  
  
5.1   Introduction  
Breast cancer is the most commonly diagnosed female cancer worldwide and the second most 
common cause of female cancer mortality worldwide. In Scotland it accounts for 12.6% of 
annual female cancer deaths, around 1,000 women each year [1]. Morbidity and mortality is 
due to relapsed, drug resistant metastatic disease, rather than the primary tumour. Metastases 
in regional lymph nodes at the time of primary surgery, have long been recognised as one of 
the most important prognostic indicators for recurrent disease [324]. In around one quarter of 
patients, lymph node metastases are present at diagnosis.  
 
Breast cancer is a hugely complex disease spectrum with distinct clinical outcomes. Intra-
tumoural heterogeneity is well recognised [325], and many studies have demonstrated 
discrepancies between expression of biomarkers in primary tumours and paired metastases. 
This is recognised both when nodal metastases are present simultaneously with the primary 
tumour [237, 326-328], and also when tumours recur later at distant sites [287, 329-331]. The 
magnitude of this variability is considerable; with discrepancies in up to 36% of patients in 
expression of ER, up to 54.2% of PR, and up to 31.6% of HER2, see table 5-1. This could 
have considerable implications on treatment decisions.  
 
The role of repeat biopsy in metastatic recurrences is becoming increasingly recognised in 
routine clinical practice [332], as treatment can change in up to one in six women. However, 
in patients who are node positive at diagnosis, current practice dictates that features of the 
primary tumour, rather than the lymph node, are used for prognostic profiling, treatment 
decisions and monitoring response to therapy in the neoadjuvant period [333]. 
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Discordance rate (%) 






Zhao et al [328] 
 
54 19.1 11.8 14.8 0 
Tawfik et al [327] 
 
103 10 16.9 31.6 18.4 
Li et al [326] 
 
107 22.4 17.8 15.9 NR 
Aitken et al [237] 
 
211 28.4 23.5 8.9 NR 
Falck et al [329] 
 
147 1 16 16 23 
Primary and later 
logo-regional  
and / or distant 
metastases 
 
Falck et al [329] 
 
36 13 33 27 18 
Lindstrom et al 
[330] 
459 32.4 40.7 14.5 NR 
Thompson et al 
[287] 
137 10.2 24.8 2.9 NR 
Sari et al [331] 
 
78 36 54.2 14.7 NR 
 
Table  5-­1.  Discordance  in  ER,  PR,  HER2  and  Ki67  in  primary  and  paired  metastatic  
breast  tumours  
NR  –  not  recorded  
 
Although disparity in IHC hormone receptor expression is well recognised between primary 
and metastatic breast cancer, differences at transcription level are not so well understood. 
Weigelt et al compared gene expression profiling in 7 paired primary and distant metastatic 
tumours, as well as post mortem samples from multiple sites in five patients, including spinal 
cord, liver, adrenal, lymph node, lung, kidney, diaphragm, and brain. In unsupervised 
hierarchical clustering, all samples from the same patient always clustered together, suggesting 
molecular profiles are maintained in distant metastases [334]. Molecular subtype, as 
determined by 70-gene signature, was the same in 6 of the 7 paired samples.  
   115  
Priedigkeit et al compared intrinsic subtype by PAM50, in 20 patients with primary breast 
tumours and brain metastases, and found concordance in 17 (85%). They also found however, 
loss of ESR1 in 9 (45%) and gain of ERBB2 in 7 (35%); with 3 of these 7 also demonstrating 
new HER2 positivity by IHC in the brain metastases [335]. Despite high concordance overall 
by subtype, there are obviously huge implications for changes in treatment in up to 45% of 
this cohort.   
 
Vecchi et al found distinct differences in molecular profiles between primary tumours and 
metastases, and proposed a 4 gene epithelial ‘metastatic signature’ that could separate 
primaries from metastases with 70-80% accuracy across 3 cohorts of 115 paired samples 
[336]. Similarly, Lee et al described differences in PAM50 intrinsic subtype between paired 
primary breast cancers and brain metastases in 8 of 17 patients (47%)  [337].  
 
We can improve on traditional clinicopathological estimates of prognosis by assessing tumour 
biology at transcriptional level [162]. Previous studies have assessed metastases which 
developed later than the primary tumour. This could reflect changes in response to treatment, 
rather than innate tumour evolution and progression. This is the largest cohort to date to 
perform gene expression profile analysis, in paired primary breast tumours and their matched 
synchronous lymph node metastases.  
 
5.2   Methods  
We identified two separate cohorts of patients to participate in this study, see figure 5-1. The 
first were historic samples from patients operated on between 1999-2002, identified from the 
South East Scotland Cancer Network (SCAN) Audit Database following approval by both 
NHS Lothians Tissue Governance Committee and Caldicott Guardians. Criteria for inclusion 
were primary breast tumours measuring 2cm or more in diameter, with 2 or more positive 
axillary lymph nodes at the time of resection. FFPE blocks were then retrieved for each patient, 
and 5µm sections cut for both RNA extraction and to prepare H&E slides.  
 
The second cohort was prospectively collected between November 2012 and January 2014, 
following approval by the Lothian Regional Ethics Committee. Patients confirmed to have a 
primary breast cancer with an involved axillary lymph node at diagnosis were included. Core 
biopsy was taken from both the breast primary tumour (P) and lymph node (N) and snap frozen 
in liquid nitrogen.  
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Clinical information for patient demographics and outcomes was collated from medical 
electronic and paper case note review.  
 
Slides were prepared and stained with H&E from each sample in both cohorts and reviewed 
with a consultant pathologist. Samples with low cellularity or low tumour content were 
excluded.  
 
RNA extraction from FFPE tissue was carried out using the Prelude kit (NuGEN) as per the 
manufactures standard protocol. Briefly, tissue underwent deparaffinisation using xylene and 
washing with ethanol, then lysis and digestion using proteinase K and binding buffer with β-
mercaptoethanol. Preparations then underwent column purification with DNAse treatment and 
RNA was then eluted in nuclease free water and stored at -80oC until further use.  
 
In fresh frozen biopsies, tissue was homogenised and RNA was extracted using the RNeasy 
Mini Kit with RNAse-free DNAse treatment (Qiagen), as described previously [338].  
 
All RNA was reverse transcribed to cDNA then amplified using the Ovation WTA System 
(NuGEN). Amplified cDNA was labelled using the Encore BiotinIL module (NuGEN) 
purified with the MinElute purification kit (Qiagen) and hybridised to Illumina HT12v4 Whole 
Genome Expression BeadChips. At each step of the process RNA concentration and purity 
was assured with Nanodrop 2000c (Thermo Scientific), before progressing to the next stage.  
 
Data was processed and analysed using the statistical programming language R. Illumina 
probe profiles were quantile normalised using the lumi package [258] and mapped to Ensembl 
gene sequences using reMOAT [259], BioMart and a custom BLAST sequence search. 
Undetected probes (p>0.05) were removed. Cross-platform normalisation (XPN; 
ArrayMining) [257, 321, 322] was used to correct for batch effects between the FFPE and 
fresh frozen samples.  Unsupervised hierarchical clustering and gene expression heatmaps 
were generated in MeV; (TM4 Microarray Software Suite) using Euclidean distance with 
complete linkage following gene mean-centering performed in Cluster 3.0. Intrinsic subtype 
was determined by proximity to centroid of Sorlie subtype, based on expression of 438 
intrinsic gene list [43]. Multidimensional scaling was performed in R with scaling plots 
generated in JMP10 (JMP Software, USA). 
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5.3   Results  
From the historic cohort 139 samples from 52 patients were identified and we prospectively 
collected 44 samples from 22 patients. Unfortunately, a large number of FFPE samples failed 
various stages of RNA processing due to insufficient quantity or quality and had to be 
excluded. Microarray data was generated for 68 samples from 31 patients in total, figure 5-1. 
 
Clinicopathological features were available for 30 of the 31 patients included on microarray. 
Multiple features of adverse prognosis were found, not unexpectedly. Most tumours were 
grade 2 or 3; 53.3% had lymphovascular invasion, and the median number of positive nodes 
was 6 per patient. The majority (63.3%) underwent mastectomy as the breast surgical 
procedure, and all patients underwent axillary node clearance rather than axillary node sample 
or sentinel node biopsy, reflecting the heavy disease burden in the axilla. See table 5-2. 
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Table  5-­2.  Characteristics  of  cohort  
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5.3.1   Molecular  portraits  of  nodes  are  distinct  from  primary  tumours  
Unsupervised hierarchical clustering of the 500 most variable genes across all samples 
grouped only 12 of 31 primaries and nodes (39%) together. In most patients, their P or N more 
resembled a cancer from another patient than its own paired P or N, figure 5-2.  
 
Interestingly however, 6 patients had 1 P matched with 2 N samples. In 2 of these, all 3 
clustered together, and in a third, both nodes clustered together, albeit separate from the 
primary. This implies a gene signature common to lymph nodes in these patients.  
 
Overall the P and N samples trended to clustering separately; orange N towards the left of this 
heatmap, pink P samples towards right. This may be due to distinct genes related to site of 
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Figure  5-­2.  Unsupervised  HCL  of  500  most  variable  genes  in  all  samples  
Pink  –  primaries,  Orange  –  nodes.    
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5.3.2   Changes  between  primary  tumours  and  nodes  vary  between  patients  
The number of genes with greater than 2-fold change (>2FC) between P&N was used to 
categorise paired samples into ‘least changed’ (<130 genes with >2 FC) and ‘most changed’ 
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In the 10 most changed tumours, multidimensional scaling of the 500 most variable genes 




Figure   5-­4.   Multidimensional   scale   of   500   most   variable   genes   in   most   changed  
samples  
Pink  –  primary,  orange  –  node,    MDS  –  multidimensional  scaling  plot  
Left   shows   distribution   of   all   samples.   Right   shows  matched   samples   from   same  
patient  demonstrating  consistent  changes  between  P&N.    
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Across all samples, again consistent changes between matched P&Ns were seen, figure 5-5.  
 
Figure  5-­5.  Multidimensional  scaling  plot  of  all  samples  based  on  expression  of  500  
most  variable  genes.    
Pink  circle  –  primary,  orange  square  -­  node;;    




   125  
5.3.3   Intrinsic  subtype  is  not  maintained  in  primary  tumour  and  nodal  metastases    
When categorised by Sorlie subtype, most primary tumours were luminal A (15 of 31, 48.4%), 
followed by luminal B (11 of 31, 35.5%).  
In the nodes, most were luminal B (22 of 37, 59.5%), followed by luminal A (13 of 37, 35.1%). 
A larger proportion of nodal metastases became luminal B than any other subtype, however 
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In paired samples 12 of 31 patients (39%) had a different molecular subtype in the node 
compared with the primary. In changed samples, the node tended to be a poorer prognostic 
subtype than the primary, see figure 5-7. In 6 of the 12 which changed subtype (50%), a 





Figure  5-­7.  Change  in  subtype  between  primary  and  node  
Red  lines  denote  patients  in  ‘most  changed’  group  (>370  genes  with  >2FC  between  
P&N)  
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In 6 patients with one primary and 2 matched nodes, 2 tumours changed subtype, shown in 




Figure  5-­8.  Change  in  subtype  in  2  patients  with  P+2N  
 
5.3.4   Changed  tumours  and  survival  
Progression free and overall survival was compared in the ‘least changed’ and ‘most changed’ 
groups. However, there was a lack of events in the ‘least changed’ group, all of whom 
originated from the prospectively collected cohort, therefore no comparison was possible. 
Follow up period in this cohort was inevitably much shorter than the historic cohort 
(prospective - median 356 days, range 146-551; historic - median 4,695 days, range 4,458-
4,911 days). 
Of the 13 patients in the historic cohort, survival data was available for 12.  
There were 9 recurrence events, with a median progression free survival of 959 days (range 0-
4,676 days). There were 8 breast cancer specific deaths, at a median of 1,373.5 days (range 
582 – 1,833 days).  
 
5.3.5   Expression  of  ESR1,  PGR  and  ERBB2  
Mean level of log2 expression across all samples was calculated for ESR1, PGR and ERBB2. 
A single sample within a pair, with expression outwith 2 standard deviations of the mean was 
highlighted as a discordance.  
Discordance rates between P and N in all patients were: 
ESR1 - 10 of 31 (32.3%); loss in 3, gain in 6, 1 patient with 2 N – 1 gain, 1 loss, 
PGR - 6 of 31 (19.4%); loss in 3, gain in 3, 
ERBB2 - 5 of 31 (16.1%); loss in 3, gain in 2.  
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5.4   Discussion  
We have demonstrated metastatic axillary lymph nodes are distinct from their matched 
primary in up to 39% of patients. The number of genes changed in the node compared to the 
primary, varies markedly between patients. However, even in those with fewer numbers of 
genes changed, there can be discrepancy in intrinsic subtype. Metastases tend to be a poorer 
prognostic subgroup than their primary. Tumour biology is established as a marker of 
prognosis and recent guidelines have recommended assessment of molecular subtype as a 
routine of care [339].  
 
Previous studies have focused on discrepancy in subtype in metastases developed at a later 
date. We have shown however, there is discordance even at the time of diagnosis, and primary 
surgery in node-positive disease. There was no neoadjuvant therapy given to this cohort, which 
removes the influence of drug therapies as a cause of genomic aberrations, proving these 
changes are due solely to tumour evolution and progression.  
  
Our findings support the study by Vecchi which demonstrated synchronous lymph nodes were 
distinct from their matched primary [336]. Similarly, our results are comparable to the Lee 
study, where discordance in PAM50 subtype between paired primary breast and brain 
metastases was 47.1% (8 of 17). Furthermore, 5 of 6 patients in that study, with luminal A 
breast tumours, changed subtype in the brain metastases (three to HER2, two to luminal B) 
[337]. This parallels the direction of change observed in our cohort. 
 
Our results contrast however, with previous autopsy studies where tumour specimens from 
multiple metastatic sites in the same patient always clustered together [334, 340]. Weigelt also 
profiled metastatic axillary lymph nodes with paired primaries alongside the autopsy tissue; 
and found 6 of 8 primaries and nodes paired together, which is less concordant than the 
primaries and distant metastases [334]. This may reflect organ specific heterogeneity in gene 
expression. In our study, nodes and primaries trended towards opposite ends of the 
dendrogram. Gene signatures predictive of metastatic potential to particular distant sites have 
been proposed. Lee described a 5-gene signature which could distinguish brain metastases 
from breast primaries [337]. Szekely et al reported frequent loss of hormone receptors in lung 
and liver metastases (10 of 16 patients) but not at other sites in their autopsy study of 25 
patients with multiple metastases profiled (up to 10 per patient). They defined St Gallen 
subtype by IHC, and found subtype discordance between primary and metastases in 52% (13 
of 25) [341]. Discordance between multiple samples of metastases from the same site however, 
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was lower. They also observed the most frequent change was luminal A primary to luminal B 
metastases.  
 
Flack et al also assessed subtype by St Gallen IHC criteria in paired primary and synchronous 
lymph nodes. Discordance in receptor status was: ER 1%, PR 16%, HER2 16% and Ki67 23%, 
but there was no significant discordance in overall St Gallen subtype [329]. In 15 patients 
where subtype changed from luminal A primary to non-luminal A node, mortality was 
comparable to patients with non-luminal A stable disease both in primary and node. Similarly, 
in 13 patients with non-luminal A primary and luminal A node, mortality risk was less than 
patients with stable non-luminal A disease at both sites. Although these are very small 
numbers, achieving luminal A in nodal metastases seems to confer better prognosis. One can 
postulate nodal subtype may have more clinical relevance in prediction of prognosis than 
primary tumours in node positive disease.  
 
There are limitations of our study however, which must be considered. This included 2 quite 
distinct cohorts, one of which was selected from historic records and was biased for heavy 
burden disease; both in terms of number of positive nodes, and primary tumour size. The 
quality and quantity of RNA extracted from the historic FFPE tissue was markedly poorer than 
the prospective frozen cohort, another source of bias. The initial planned cohort was 
subsequently substantially reduced, therefore no survival analysis was feasible.  
 
Nonetheless our findings have immense clinical significance, with implications in treatment 
of node positive disease in the neoadjuvant and adjuvant setting. In our cohort, 3 patients lost 
ER and 3 lost HER2 between primary and node. Current practice dictates they would endure 
adjuvant targeted endocrine and HER2 therapies, however had the node been profiled 
treatment would be markedly different. Increasingly we are recognising the heterogeneity of 
late recurrence and the need to re-biopsy rather than base treatment on historic tissue [287]. 
Despite this, synchronously resected involved metastatic lymph nodes are not routinely 
analysed for hormone receptors or biomarkers, therefore have no influence on treatment plans 
or predicting prognosis.  
 
5.5   Conclusions  
Involved metastatic lymph nodes at diagnosis impact on survival. Classifying cancer 
molecular phenotype and estimating prognosis based only on the primary cancer misclassifies 
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significant numbers of patients. Classification of prognosis, and treatment based on the nodal 
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6   Overall  Conclusions  and  Perspectives  
The results presented in this thesis illustrate overwhelmingly the enormous value of assessing 
sequential repeat biopsies in breast cancer patients at different time points in their disease. 
Breast cancer is a hugely complex and constantly evolving process. High throughput 
technologies have proven invaluable in advancing our understanding of its intricacies. The 
work in this thesis has made valuable contributions to our understanding of breast cancer, and 
also poses significant and important questions which are applicable in routine patient care. 
 
6.1   Validation  of  on-­treatment  biopsy    
In the non-treated cohort, most tumours (18 of 25) clustered together at baseline and at second 
sample. This confirms the individual molecular portrait of early breast cancers is maintained 
over time, when no treatment is given. Neoadjuvant treatment downstages large primary 
tumours [71] and increases rates of breast conservation [138]. It also allows assessment of 
molecular response to drugs, with prediction of long-term response to endocrine therapy 
feasible after just 2 weeks [149]. In letrozole treated ILC and IDC tumours, a distinct gene 
signature at baseline differentiated them from each other, and was maintained over the 
treatment period. The global gene changes in response to letrozole however, were almost 
uniform in both.  
 
In our non-treated cohort, there was little overlap (19%) in the genes changed compared with 
letrozole treated tumours. This affirms changes in treated tumours are truly due to drug effects. 
Furthermore, on treatment measure of biomarkers, including Ki67, are more prognostic and 
predictive of response than they are at baseline, validated first in IMPACT [30], and more 
recently in Z1031B [193]. This non-treated cohort validates the use of a second biopsy, to 
assess on-treatment biomarkers, such as changes in proliferation, confirming changes are truly 
drug related, rather than reflective of tumour evolution. 
 
6.1.1   Surgical  specimens,  an  underutilised  resource?  
We have highlighted a minority of patients however (7 of 25), where there were changes 
between the core biopsy and surgical specimen, in whom sequential samples did not cluster 
together. Others have also described changes in small numbers of patients, between core 
biopsy and surgical specimen with no intervening treatment [247] resulting in discordance in 
subtype assignment also [248]. This of course has major implications for adjuvant treatment.  
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Currently we use the core biopsy to determine ER, PR and HER2. We have affirmed that the 
core biopsy is truly reflective of overall tumour biology, however intra-tumoural heterogeneity 
is renowned. An alternative approach would be assessment of sequential biopsy over time, 
which may offer a more realistic representation of the representative inherent heterogeneity 
and tumour biology. Reanalysing biomarkers at surgical resection, if introduced into routine 
care, could highlight changes inherent to natural tumour evolution over time, and identify 
high-risk patients early. 
 
6.1.2   Use  of  routine  peri-­operative  treatment  
In IMPACT, 52 of 56 (93%) patients showed some suppression of proliferation with 2-weeks 
of anastrozole [30], suggesting that nearly all ER+ patients derive some benefit from 
aromatase inhibitor treatment. The use of short course pre-surgical and peri-operative 
endocrine treatment is becoming increasingly routine. POETIC will assess long-term outcome 
in patients who received peri-operative AI [194] in due course. This highlights an exciting 
opportunity to assess repeat sample after short course treatment which could be incorporated 
into routine practice, to provide a more reliable estimate of prognosis. Furthermore, this could 
address important questions prospectively for adjuvant treatment.  
 
6.1.3   Implications  for  adjuvant  treatment  
Sequential and combination drug therapy approaches have proven effective in the management 
of metastatic ER+ breast cancer. Everolimus [218], fulvestrant [110], and palbociclib [233] 
given with AIs, have restored endocrine sensitivity and improved progression free survival. 
The success in the metastatic setting has prompted phase III trials to explore their use in the 
neoadjuvant period. ALTERNATE and NeoMONARCH will assess neoadjuvant fulvestrant 
and abemaciclib respectively, given alone or in combination, with anastrozole over anastrozole 
alone, to assess clinical outcomes and on-treatment Ki67. NeoMONARCH has shown greater 
interim Ki67 reduction with abemaciclib, but survival data is yet awaited [196].  
 
If neoadjuvant or perioperative treatment with one agent proves ineffective, this could be 
recognised at the time of surgery, from the resection specimen. This provides the option to 
switch to an alternative endocrine agent, or to add a second targeted drug, such as a CDK4/6 
inhibitor or mTOR inhibitor, in the adjuvant period, in order to improve outcome. This would 
have enormous potential as it could identify earlier, patients in whom standard endocrine 
therapy is insufficient, and alternative agents could be employed, sparing them from 
ineffective treatment.  
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6.2   Molecular  changes  in  metastases  
6.2.1   PIK3CA  mutation  status  is  stable  in  metastases  
PIK3CA status was largely maintained between primary tumour and secondary event with 
change in only 14 of 89 patients (15.7%). Change was significantly more likely in a second 
new primary breast cancer rather than any other secondary event. This does not support the 
theory that PIK3CA mutation is gained as a mechanism of resistance, unlike evidence for ESR1 
[220]. In BELLE2, PIK3CA mutation was a biomarker of response to buparlisib [219]. Our 
findings confirm assessment is possible from archived FFPE samples and is consistent over 
time, so diagnostic mutation status could be used as a biomarker in later years. In the future 
serial assessment of ctDNA may prove useful in this role, however further validation and 
standardised measures will be required before this is available in the clinic [342]. 
 
6.2.2   Nodal  metastases  are  distinct  from  primary  tumours  
A significant proportion (12 of 31, 39%) of patients had discordance in molecular subtype 
between nodal metastases and their matched primary, most commonly becoming more poorly 
prognostic. Similar changes have been demonstrated in asynchronous brain metastases 
previously [335, 336] but the findings demonstrated herein, confirm these changes at diagnosis 
and at primary surgery in node positive patients. Classifying molecular phenotype and 
estimating prognosis based only on the primary tumour could misclassify significant numbers 
of patients and potentially offer ineffective treatments, or deny patients from the most 
appropriate options. Most node positive patients would be considered for neoadjuvant 
chemotherapy. This presents another opportunity for consideration in the future where 
primaries and nodes pre and post neoadjuvant treatment could be assessed.  
 
6.3   Limitations  and  future  directions  
A major limitation and frustration during this project was the rate of success in using FFPE 
tissue for RNA microarray analysis from the primaries and nodes cohort. The initial 139 
specimens reduced eventually to 36 after poor yield during RNA extraction and subsequent 
exclusion of further samples because their matched pair was no longer available. The change 
in subtype is a potentially major clinical finding however, it lacks significance as the small 
numbers precluded any valuable survival analysis. Consequently, we have not confirmed that 
the subtype changes observed are of clinical relevance. Nonetheless it highlights a very 
important observation which is worthy of further investigation. 
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Furthermore, gene expression profiling is costly and not routinely available. IHC or qRT-PCR 
however are more routinely available and could be employed at serial biopsy, whether this be 
in positive node or resected surgical primary. Assessments of molecular subtype and prognosis 
are possible through IHC and qRT-PCR indices [149, 169, 170, 172, 188]. This may be helpful 
in providing a assessment of tumour biology. However, commercially available assays, 
including OncotypeDx and PAM50 are only offered through centralised laboratories to 
minimise error.  
 
Future work will also involve assessment of alternative RNA extraction and processing 
methods specific to FFPE tissue [343]. FFPE blocks are readily available and archived tissue 
could represent an amazing resource to assess retrospective biomarkers in specific cohorts. 
Expansion of the primaries and nodes cohort with further historic samples will be explored 
and compared with survival data to determine the prognostic significance of subtype 
discordance.  
 
A further option to be explored is combining data from these cohorts with large publicly 
available datasets of samples with comparable cohorts [257]. This may help to validate, or 
indeed may refute, the differences observed here, including change between core biopsy and 
resection, and subtype discordance between primary and node.  
 
6.3.1   Improving  estimates  of  prognosis  and  prediction  to  treatment  
There is a need to distinguish high risk luminal disease from those with excellent prognosis to 
stratify chemotherapy combined with endocrine therapy, over endocrine therapy alone [188], 
in both adjuvant and neoadjuvant treatment. TAILORx identified low risk ER+ node negative 
patients who could forego adjuvant chemotherapy [176] with similar evidence from the use of 
PAM50ROR, where a subgroup of ER+ node negative patients had >95% survival without 
adjuvant chemotherapy [179]. There is disagreement between clinicopathological and 
molecular assessment of risk frequently. This presents a clinical dilemma, and an area where 
further research is necessary. RASTER demonstrated discordance between 70-gene signature 
and Adjuvant! Online, St Gallen classification and NPI in 37%, 39% and 27% respectively 
[185]. MINDACT also confirmed discordance between clinical and genomic estimation of 
risk but was underpowered to confirm benefit of chemotherapy in the discordant groups [187]. 
Further evaluation is also required in patients deemed intermediate risk in genomic scoring. 
Combining clinical features and biological biomarkers is an emerging option, with evidence 
of superiority over clinical features or biological markers alone [179, 189]. A Chemo-
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Endocrine Score has been proposed, where a gene signature on treatment is predictive of 
endocrine sensitivity and of chemotherapy resistance. This can improve on ROR score and 
will help to further evaluate best management of intermediate risk score patients [344].  
 
A further emerging strategy is the role of the liquid biopsy. Early evidence exists for its utility 
as a biomarker in metastatic disease [345]. Recently it has also shown promise in the adjuvant 
setting [342]. This could revolutionise care for patients, with prediction of recurrence before 
any measurable disease burden has emerged, potentially.  
 
We have affirmed molecular changes in both treated and non-treated samples; and both 
discordances and similarities between different cohorts of primaries and metastatic biopsies. 
This reflects the complex evolution of ER+ breast cancers. This project has reinforced the 
benefits of the neoadjuvant period as an opportunity to explore biomarkers. Additionally, we 
have further corroborated the advantage of profiling matched patient samples over time, 
treatment and at different sites of disease, as a powerful opportunity to explore biomarkers and 
estimates of prognosis, in a strive towards personalised medicine.  
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8   Supplementary  
8.1   Proliferation  genes  are  un-­changed  in  non-­treated  samples  
Assessment of a panel of proliferation associated genes revealed consistent down-regulation 
in second biopsy in letrozole-treated tumours. No consistent trend in proliferation genes in 
non-treated tumours was observed.  
 
Figure  8-­1.  No  consistent  changes  in  proliferation  genes  in  non-­treated  samples  
Heatmap   of   proliferation   associated   genes   in   letrozole-­treated   and   non-­treated  
samples.  Samples  are  ordered   left   to   right  by   interval   from  core  biopsy   to  surgery  
(days),  in  letrozole  treated  and  non-­treated  cohorts.  Colours  relative  to  pre-­treatment  
sample.  Green  –  lower  expression,  red  –  higher  expression      
 
 
          
